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   Cutaneous  melanoma  remains  the  deadliest  form  of  skin  cancer,  with  a 
diagnosis of metastasis indicating a median survival rate of less than a year. 
Solar  ultraviolet  (UV)  radiation,  especially  childhood  sun  exposure,  is  an 
important etiological risk factor of melanoma. Previous studies determined that 
mice selectively lacking the nuclear hormone receptor Retinoid X Receptor α 
in  epidermal  keratinocytes  (RXRα
ep-/-)  developed  a  higher  number  of 
aggressive  melanocytic  tumors  compared  to  wild  type  mice  after  two-step 
chemical  carcinogenesis,  suggesting  a  novel  role  of  keratinocytic  nuclear 
receptor  signalling  during  melanoma  progression.  We  then  discovered  a 
progressive  loss  of  RXRα expression  in  epidermal  keratinocytes  during  
 
melanoma progression in humans. We also investigated the contributions of 
CDK4
R24C/R24C and keratinocytic RXRα to influence metastatic progression in a 
mouse model by generating RXRα
ep-/-/CDK4
R24C/R24C bigenic mice containing 
an  activated  cyclin  dependent  kinase  4  (CDK4),  besides  lacking 
RXRα in epidermal  keratinocytes.  Those  bigenic  mice  developed  malignant 
melanomas  that  metastasized  to  regional  lymph  nodes  after  carcinogen 
exposure.  Expression  of  several  keratinocyte-derived  growth  factors 
implicated in melanomagenesis were upregulated in the skin of bigenic mice, 
and recruitment of RXRα was shown on the promoters of endothelin-1 (Edn1) 
and hepatocyte growth factor (Hgf). We then confirmed a downregulation of 
factors  (FAS,  E-cadherin  and  PTEN)  implicated  in  apoptosis,  invasion  and 
survival within the melanocytic tumors. 
   To  further  evaluate  the  paracrine  role  that  EDN1  has  on  melanocyte 
activation, we utilized a transgenic mouse model where the gene encoding 
Edn1 was selectively ablated from epidermal keratinocytes using the Cre-LoxP 
strategy to create the EDN1
ep-/- knockout mouse line. We discovered a direct 
in vivo transcriptional regulation of keratinocytic Edn1 by the tumor-suppressor 
p53  in  epidermal  keratinocytes  in  response  to  UV  irradiation.  We  also 
demonstrate  that  in  vivo  disruption  of  keratinocyte-derived  EDN1  signaling 
alters  melanocyte  proliferation  and  decreases  epidermal  and  dermal 
melanocyte populations in both normal and UV exposed mouse skin. EDN1  
 
also has a protective role against UVR-induced DNA damage and apoptosis 
and similar effects on UV-induced melanocyte proliferation and DNA damage 
are  observed  in  p53-null  mice.  Inhibition  of  EDN1  signaling  by  topical 
application of an EDNRB antagonist BQ788 on mouse skin also recapitulates 
epidermal  EDN1  ablation.  Furthermore,  treatment  of  primary  murine 
melanocytes with BQ788 abrogates signaling downstream of this receptor.  
   Taken  together,  these  studies  demonstrate  the  contribution  of  RXRα 
regulated keratinocytic paracrine signaling during the cellular transformation 
and malignant conversion of melanocytes. Also, they establish an essential 
role of EDN1 in epidermal keratinocytes to mediate UV-induced melanocyte 
homeostasis in vivo.   
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1.1  Abstract 
 
   Skin  homeostasis  is  maintained,  in  part,  through  regulation  of  gene 
expression orchestrated by type II nuclear hormone receptors in a cell and 
context specific manner. This group of transcriptional regulators is implicated 
in various cellular processes including epidermal proliferation, differentiation, 
permeability barrier formation, follicular cycling and inflammatory responses. 
Endogenous  ligands  for  the  receptors  regulate  actions  during  skin 
development and maintenance of tissue homeostasis. Type II nuclear receptor 
signaling is also important for cellular crosstalk between multiple cell types in 
skin. Overall, type II nuclear receptors are critical players in keratinocyte and 
melanocyte biology and present targets for cutaneous disease management.   3 
 
1.2  Mechanisms of action for type II nuclear receptors 
 
   Transcriptional  control  of  gene  expression  is  achieved,  in  part,  through 
protein factors bound to regulatory elements present on the chromatin. The 
type II nuclear receptors (NR), belonging to the superfamily of steroid-thyroid 
hormone  nuclear  receptors,  contribute  to  the  cellular  responses  of 
physiological demands (Evans, 1988; Mangelsdorf et al., 1990; Mangelsdorf et 
al.,  1995;  Chambon,  1996).  Transcriptional  modulation  is  achieved  by 
structural adjustments initiated through ligand binding. Present throughout the 
animal  kingdom,  this  family  of  environmental  sensors  contributes  both 
positively  and  negatively  to  gene  expression.  This  differential  regulation  is 
useful  in  organismal  development  and  homeostasis,  though  it  is  also 
implicated in a variety of pathological conditions. The present review will only 
detail  the  contributions  of  type  II  NRs  towards  epidermal  and  follicular 
development and homeostasis, and in skin diseases. Particular emphasis is 
given  on  melanocyte  biology  and  in  melanomagenesis  arising  from  altered 
signaling  between  keratinocytes  and  melanocytes,  while  highlighting  the 
potential therapeutic value of these pliable receptors.  
   Type  II  NRs  belong  to  a  larger  family  of  steroid  hormone  receptors,  all 
sharing  similarities  in  domain  structure  (Figure  1.1)  (Escriva  et  al.,  1998; 
Kumar  and  Thompson,  1999).  Distinct  variations  in  domain  sequence  has   4 
 
allowed for the diversification and specialization currently present within the 
family (Laudet, 1997). The DNA binding domain is highly conserved across the 
family and contains two zinc finger motifs. These domains recognize and bind 
short  response  elements,  allowing  for  both  homo-  and  hetero-dimerization 
combinations.  Two  activation  domains  called  AF-1  and  AF-2  assist  the 
receptors in dimerization and DNA binding. Variability is more evident within 
the carboxyl terminal ligand binding domain, where individual receptors have 
evolved  to  bind  a  variety  of  signaling  molecules  (Bourguet  et  al.,  2000). 
Receptors for which ligand specificity has yet to be determined are labeled as 
orphan receptors. Endogenous ligands for NRs known to be expressed in skin 
include:  all-trans  retinoic  acid  (RA)  and  9-cis  RA  for  retinoic  acid  receptor 
(RAR) (Giguere et al., 1987; Petkovich et al., 1987), 9-cis RA for retinoid-X-
receptor  (RXR)  (Mangelsdorf  et  al.,  1990;  Heyman  et  al.,  1992),  1,25-
dihydroxyvitamin  D3  (1,25-(OH)2D3)  for  vitamin  D  receptor  (VDR)  (Simpson 
and  DeLuca,  1980),  fatty  acids/lipids  for  peroxisome  proliferator-activated 
receptor  (PPAR)  (Forman  et  al.,  1995;  Kliewer  et  al.,  1995;  Kliewer  et  al., 
1997; Forman et al., 1997), oxysterols for liver X receptor (LXR) (Janowski et 
al., 1996) and triiodothyronine for thyroid receptor (TR) (Samuels et al., 1974). 
   A distinguishing feature of type II NRs is the promiscuity displayed by RXR. 
All NRs from this class form heterodimers with an isoform of RXR (α/β/γ) and 
regulate  gene  expression  in  a  ligand  dependent  fashion.  RXRα  is  able  to   5 
 
heterodimerize with some 15 NR family members and occupy direct repeat 
response  elements  present  on  the  promoters  of  target  genes  (Leid  et  al., 
1992; Kliewer et al., 1992; Willy et al., 1995; Chandra et al., 2008; Orlov et al., 
2012).  The  nonsteroidal  ligands  of  RXR/NR  heterodimers  dictate  the 
organization of complexes associated with the receptors. Serial combinations 
of  regulatory  proteins  allow  chromatin  remodeling  and  recruitment  of  basal 
factors  to  initiate  and/or  repress  transactivation  (Figure  1.2)  (Glass  and 
Rosenfeld,  2000;  Perissi  and  Rosenfeld,  2005).  Coactivators  include  ATP-
dependent chromatin remodelers, histone acetyltrasferases and the Mediator 
complex  (Dilworth  et  al.,  2000;  De  Luca  et  al.,  2003;  Blanco  et  al.,  1998; 
Fondell  et  al.,  1996;  Rachez  et  al.,  1999).  Corepressors  comprise  the  N-
CoR/SMRT assembly and histone deacetylases (Underhill et al., 2000; Yoon 
et al., 2003; Miyata et al., 1998; Lee and Wei, 1999). The large numbers of 
regulatory  factors,  as  well  as  tissue  specific  localization,  allow  NRs  to 
influence  a  diverse  range  of  gene  expression  in  a  cell  and  tissue  specific 
manner. For example, the PPARγ cofactor PGC-1 is present in adipose tissue 
but not fibroblasts, allowing a cell-type specific activation of genes related to 
adaptive  thermogenesis  (Puigserver  et  al.,  1998).  Post-translational 
modifications of co-factors such as phosphorylation, methylation, sumoylation 
and ubiquitination are also known to contribute to the extensive specificity of 
NR regulation (Hermanson et al., 2002).   6 
 
1.3  Skin morphogenesis, epidermal homeostasis and hair cycling 
 
   Skin is the largest organ in the body and is comprised of multiple cell types 
such  as  epidermal  keratinocytes,  dermal  fibroblasts  and  hypodermal 
adipocytes, besides Langerhans cells, melanocytes and endothelial cells. It 
utilizes  both  autocrine  and  paracrine  signaling  for  development  and 
maintenance  of  tissue  homeostasis  (Fuchs  and  Raghavan,  2002).  The 
outermost epidermal layer provides a protective barrier to environmental and 
physical  stresses  and  constantly  progresses  through  cycles  of  proliferation 
and  differentiation.  Basal  keratinocytes  located  on  the  innermost  epidermal 
basement  membrane  (separating  epidermis  from  the  underlying  dermis) 
generate daughter cells, which undergo committed differentiation that give rise 
to  ordered  layers  of  suprabasal  early-  and  late-differentiated  keratinocytes. 
Appendages  such  as  hair  follicles  and  sebaceous  glands  (SGs)  are 
invaginated  into  the  mesenchymal-derived  dermal  layer.  Different  resident 
multipotent skin stem cell (SC) niches contribute to the renewal, maintenance 
and  repair  of  the  epidermal  tissues  of  the  skin,  including  interfollicular 
epidermis (IFE), hair follicles and SGs (Fuchs, 2007). Epidermal SCs play a 
crucial role in maintaining tissue homeostasis by supplying new daughter cells 
to replace those constantly lost during turnover or following injury. Bulge SCs 
are known to maintain normal follicle homeostasis and can also contribute to   7 
 
the  formation  of  IFE  following  skin  injury  and  during  wound  healing. 
Melanocytes  are  also  located  within  the  hair  follicles  where  they  primarily 
contribute pigmentation to coat color. In humans, IFE melanocyte populations 
rely on keratinocytic paracrine signaling for assistance in photoprotection from 
solar ultraviolet irradiation (Nishimura, 2011). 
   Type II nuclear receptor signaling contributes to the perpetual renewal of 
keratinocytic layers, maintenance of the epidermal permeability barrier (EPB) 
and  follicular  cycling.  Impaired  expression  or  function  of  these  receptors  is 
implicated  in  aberrant  proliferation  and/or  differentiation  of  epidermal  tissue 
and alopecia (hair loss). The promiscuous role that RXRs play in type II NR 
signaling  hints  to  the  impact  that  impaired  RXR  expression  or  activity 
influences receptor signal transduction. Although many of RXRs heterodimer 
partners are implicated in a wide variety of skin diseases, in many cases these 
pathologies  could  instead  be  associated  with  compromised  RXR  mediated 
gene  regulation.  Regardless,  only  studies  that  have  specifically  indicated  a 
specific role for RXR function will be discussed here. RXRs play a critical and 
varied  role  in  epidermal  differentiation  and  EPB  maintenance.  RXRα,  the 
primary  isoform  in  skin  and  hair  follicles,  has  stronger  expression  levels 
compared to RARs, and RXRα/RARγ  heterodimer appears to be the major 
retinoid transducing element in epidermal biology (Fisher et al., 1994; Billoni et 
al., 1997; Feng et al., 1997). RXRα/RARγ heterodimerization is also critical in   8 
 
the development and formation of epidermal lamellar granules by repression 
of target genes, as RARγ agonists promote lamellar granule defects in murine 
skin. Similarly, RXRα/PPARβ/δ heterodimers are equally important to stratum 
corneum homeostasis through activation of gene transcription (Calleja et al., 
2006).  
   The importance of vitamin A signaling to cutaneous homeostasis has long 
been observed. Although, comprehensive studies have investigated multiple 
proteins along this pathway in skin (such as retinoic acid binding proteins), this 
review will focus primarily on RARs in human and rodent skin, particularly the 
role of RARγ (Fisher et al., 1994; Chapellier et al., 2002). RA is widely used as 
a  therapeutic  against  various  skin  diseases  due  to  its  inhibitory  effects  on 
keratinocytic  terminal  differentiation,  besides  regulating  keratinocyte 
proliferation and apoptosis, through modulation of RAR target genes (Lee et 
al., 2009). Management of keratin expression, which in turn dictates status of 
epidermal  differentiation,  is  a  known  regulatory  mechanism  of  cutaneous 
RARs  (Tomic  et  al.,  1990;  Navarro  et  al.,  1995;  Virtanen  et  al.,  2010). 
Unfortunately, the use of pan-retinoids is limited due to unwanted side effects 
such  as  skin  irritation,  hypertriglyceridemia,  bone  toxicity  and  teratogenicity 
(Chandraratna, 1998; Altucci and Gronemeyer, 2001). In order to utilize these 
efficacious compounds in a dermatological setting, receptor-selective retinoids   9 
 
in parallel with prophylactic lipid management therapies may provide clinical 
benefits with decreased risk of toxicities.  
   Early  studies  have  elucidated  the  synthesis  of  pre-hormone  25-
hydroxycholecalciferol (calcifediol) by murine epidermal basal cells that acts in 
a  paracrine  manner  for  the  CYP27B1  and  VDR  expressing  differentiated 
keratinocytes (Rizk-Rabin et al., 1994). Typical of the type II nuclear receptors, 
1,25(OH)2D3-induced  VDR  activation  inhibited  proliferation  and  promoted 
differentiation  of  keratinocytes,  though  VDR/RXRα  heterodimers  can 
transactivate keratinocytic genes independent of 1,25(OH)2D3 binding (Ellison 
et  al.,  2007).  DeltaNp63alpha,  a  critical  regulator  of  epidermal  biology,  is 
known  to  directly  control  VDR  expression  in  murine  skin  and  mediate  its 
function  in  a  ligand-independent  manner  (Kommagani  et  al.,  2009).  Mice 
bearing a targeted ablation of VDR present a large number of pathological 
properties in the skin, including progressive alopecia and dermal cysts as well 
as decreased expression of epidermal differentiation markers (Yoshizawa et 
al.,  1997;  Xie  et  al.,  2002).  By  expressing  in  discrete  epidermal  locations, 
VDR-interacting coactivators contributed divergent roles towards keratinocyte 
proliferation and differentiation (Oda et al., 2009; Bikle et al., 2010). VDR and 
its  associated  cofactors  also  contributed  to  lipid  production  and  epidermal 
barrier  formation.  Genetic  network  analysis  has  implicated  VDR  as  a 
necessary  regulator  of  skin  barrier  formation  and  predicts  the  phenotype   10 
 
characterized  in  the  VDR-null  mice  (Quigley  et  al.,  2009).  Many  epidermal 
genes induced by WNT/β-catenin contain VDR response elements and were 
activated  independently  of  TCF/LEF,  implying  that  it  is  part  of  a  TCF/LEF-
independent  aspect  of  WNT  signaling  (Palmer  et  al.,  2008).  Likewise, 
depletion of follicular keratinocyte populations in VDR-null mice was linked to 
aberration of the canonical WNT pathway (Cianferotti et al., 2007).  
   Alopecia  is  a  commonplace  in  hereditary  resistance  to  1,25(OH)2D3  and 
VDR expression is seen in the outer root sheath keratinocytes and dermal 
papilla of follicles, increasing during late anagen and catagen (Reichrath et al., 
1994). The transcriptional repressor hairless (HR) co-localized with VDR in the 
outer root sheath of hair and has been shown to inhibit target genes leading to 
hair  cycle  progression  (Haussler  et  al.,  2010).  Another  VDR  cofactor  and 
critical  subunit  of  the  transcriptional  coactivator  complex  Mediator  (MED), 
MED1, has been recently linked to hair cycling and epidermal proliferation and 
differentiation. Selective ablation of MED1 in keratinocytes presents a similar 
phenotype to VDR or HR ablation (Oda et al., 2012). miR-125b is a known 
repressor  of  skin  differentiation  in  the  bulge  region  of  the  hair  follicle  and 
expressing miR-125b in SC progeny significantly downregulated VDR activity 
(Zhang et al., 2011).  
   PPARβ/δ expression was seen in both basal and suprabasal layers of the 
normal human epidermis, while PPARα  and PPARγ expression was confined   11 
 
to  suprabasal  epidermal  cells  and  was  linked  to  squamous  differentiation 
(Westergaard  et  al.,  2001).  PPARs  are  transcriptionally  regulated  by  AP-1, 
C/EBP  family  members  and  p63,  the  master  regulator  of  epidermal 
morphogenesis  and  differentiation  (Di-Poi  et  al.,  2005;  Pozzi  et  al.,  2009). 
Mechanistically, inhibition of the PKC/MAPK pathway through PPAR-mediated 
PKCα-ubiqutitination  has  been  implicated  in  reduction  of  epidermal 
proliferation (Kim et al., 2005). All PPAR isoforms were expressed in human 
hair follicle cells while PPARγ ablation in mice mimicked a human scarring 
alopecia phenotype (Karnik et al., 2009; Ruge et al., 2011). 
   The  ability  of  LXRs  to  act  as  environmental  cholesterol  sensors  enables 
them  to  contribute  to  consistent  epidermal  turnover  which  support  a  sound 
EPB. LXRα/β are expressed in all layers of the human epidermis, as well as in 
the  outer  root  sheath  and  SG,  and  the  LXR  agonists  oxysterols  act  on 
epidermal keratinocytes by reducing proliferation and inducing differentiation 
(Komuves et al., 2002). One proposed mechanism of LXR mediated induction 
of  keratinocytic  differentiation  is  influencing  the  binding  of  transcriptional 
complex AP-1 to target genes. ChIP-on-chip studies investigating LXRβ/RXRα 
binding in human keratinocytes revealed a strong correlation to AP-1 response 
elements, with up to 77% of all LXRβ/RXRα binding sites associated with AP-1 
motifs  (Shen  et  al.,  2011).  This  could  indicate  LXR  involvement  in  the   12 
 
pathogenesis  of  certain  diseases  that  present  with  abnormal  keratinocytic 
differentiation and/or compromised barrier function. 
   Thyroid-stimulating hormone receptor signaling is commonly associated with 
cutaneous biology, though TR ligand binding is also known to contribute to 
epidermal homeostasis. Resistance to thyroid hormones is a syndrome with a 
wide variety of symptoms and is connected to TRβ mutations in in both mice 
and humans (Usala et al., 1990; Forrest et al., 1996). Follicular TRβ is the 
predominant isoform expressed within human skin and one phenotype of the 
disease linked to aberrant TRβ signaling is alopecia (Billoni et al., 2000; Guran 
et al., 2009). In support of a role for TRβ in hair cycle homeostasis, thyroid 
hormones and TRβ-selective thyromimetics are able to induce hair growth in 
both  murine  and  simian  models,  as  well  as stimulate  intrafollicular  melanin 
production  (van  Beek  et  al.,  2008;  Li  et  al.,  2010).  TRs  bind  to  conserved 
keratin response elements located in the promoter region of epidermal keratin 
genes and can directly control their transcription. One proposed mechanism of 
these genes involves transcriptional repression in the presence of a liganded 
TR receptor. In this scenario, proteins typically seen as components of a co-
activator/histone  acetylase  complex  display  repressive  tendencies  in  the 
presence  of  liganded  receptors  while  co-repressors  act  as  activators  when 
unliganded  TRs  are  present  on  the  keratin  response  element  (Jho  et  al., 
2005).  Transcriptome  analyses  from  epidermal  keratinocytes  treated  with   13 
 
either thyroid hormone or vehicle display only a small number of genes that 
are differentially expressed. Among the suppressed genes (integrin β4, plectin, 
collagen XVII, MMP1/3/14) there was significant association to the blistering 
skin  disease  epidermolysis  bullosa,  implying  an  inhibitory  role  of  thyroid 
signaling to extracellular matrix maintenance (Tomic-Canic et al., 2008). 
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1.4  Inflammatory skin diseases 
 
   Cutaneous  inflammatory  disorders  are  characterized  by  irritation  and 
inflammation of the skin that can lead to patient discomfort or disfigurement. 
Psoriasis  is  a  genetic-based  cutaneous  syndrome  that  involves  epidermal 
hyperproliferation, compromised EPB and an infiltrative immune response. It 
affects around 5% of the population and is associated with additional maladies 
such as cardiovascular disease and non-melanoma skin cancer. It affects both 
sexes equally and tends to manifest within the first two decades of life (Benoit 
and  Hamm,  2007).  As  it  is  currently  incurable,  primary  treatment  options 
include prevention of infection to minimize trauma. Control of symptoms is also 
important  and  includes  the  use  of  corticosteroids,  phototherapy  and 
moisturizing creams (Menter et al., 2008). Atopic dermatitis (AD) is another 
chronic  inflammatory  skin  disease  that  is  characterized  by  itchy  skin, 
persistent infections and very early onset (Leung et al., 2004). AD is linked to 
other atopic diseases such as asthma and allergic rhinitis, and defective EPB 
function  or  environmental  insults  are  predisposing  factors  for  this 
heterogeneous  disease (Kapoor  et  al.,  2008;  Cork  et  al.,  2009).  Treatment 
options  are  similar  to  those  for  psoriasis,  while  preventing  future  allergic 
reactions is also important. Unfortunately, the roots of these diseases may be 
too  deeply  embedded  in  immune  functions  to  be  eradicated.  Due  to  early   15 
 
onset  and  lifelong  activity,  the  use  of  chronic  corticosteroid  therapy  is 
discouraged. Knowledge regarding transcriptional regulation by key factors of 
EPB  and  epidermal  proliferation  gene  networks  enhances  our  retinue  of 
therapeutic  strategies  in  these  diseases.  NR  ligands  may  be  useful  to 
modulate  multiple  pathways  in  order  to  lessen  side  effects  and/or 
concentrations of the more efficacious compounds. 
   Mice  with  an  epidermal-specific  ablation  of  RXRα  (RXRα
ep-/-)  presented 
epidermal hyperplasia, alopecia, dermal cysts and a cutaneous inflammatory 
response (Li et al., 2000; Li et al., 2001). Likewise, mice lacking both RXRα 
and RXRβ in keratinocytes (RXRαβ
ep-/-) developed a chronic dermatitis similar 
to  human  AD  patients,  elevated  serum  IgE/IgG  and  cytokine  production 
associated with Th2-type response. Importantly, thymic stromal lymphopoietin 
(TSLP)  was  strongly  upregulated  from  the  basal  keratinocytes,  potentially 
influencing  the  systemic  AD  phenotype  in  these  mice  (Li  et  al.,  2005).  To 
further support the hypothesis that loss of RXRα contributed to a derepressive 
mechanism  on  gene  expression  leading  to  inflammatory  responses, 
expression  of  RXRα has  been  reported  to  decrease  in  human  psoriatic 
lesions, with levels in progressive disease further reduced compared to stable 
stages (Feng et al., 2006). 
   Use of the anti-proliferative, pro-differentiative properties of 1,25(OH)2D3 is 
not  ideal  due  to  harmful  calcemic  effects.  Therefore,  synthetic  deltanoids   16 
 
represent  the  best  way  to  initiate  VDR  activation  for  therapeutic  or 
investigative purposes. It was previously discussed that keratinocytic RXRα/β 
ablation upregulates production of TSLP leading to an AD-like phenotype in 
the mouse. Interestingly, topical application of deltanoids also induces TSLP in 
epidermal  keratinocytes,  suggesting  the  role  of  RXR/VDR  heterodimers  in 
regulating TSLP expression in this cell type. That evidence suggests a role for 
VDR  antagonists  in  the  treatment  of  human  AD  patients  (Li  et  al.,  2006). 
Conversely, deltanoids were shown to significantly improve allergen-triggered 
eczema  in  a  mouse  model  through  increasing  populations  of  FOXP3-
expressing regulatory T cells (Hartmann et al., 2012). Further evidences are 
needed to determine how VDR transactivation can initiate anti-inflammatory 
mechanisms  if  deltanoids  are  to  become  accepted  therapy  for 
hyperproliferative epidermal disorders in the clinic.  
   The anti-inflammatory actions of PPARα offer additional treatment modalities 
for  reoccurring  skin  conditions  such  as  AD  and  psoriasis.  Stimulation  of 
epidermal  differentiation  and  reduction  of  proliferation  can  potentially  treat 
these  conditions  without  severe  side  effects  brought  on  by  glucocorticoids 
(GC). PPARα
-/- mice (with a germline deletion of the Pparα gene) subjected to 
antigen sensitization exhibit increased epidermal thickening and inflammatory 
responses compared to wild-type controls, potentially through the loss of IL-2-
mediated induction of Treg populations (Dubrac et al., 2011). PPARα
-/- skin   17 
 
also display heightened levels of both Th2- and Th1-related responses, as well 
as  enhanced  NF-κB  signaling.  Furthermore,  PPARα  expression  is 
downregulated in lesional skin of human AD patients compared to non-atopic 
individuals  (Staumont-Salle  et  al.,  2008).  Topical  application  of  PPARα 
agonists reduces the hyperplastic response in mouse skin brought on by TPA 
treatment,  in  part  through  the  reduction  of  inflammatory  cytokines.  Similar 
results  were  seen  in  oxazolone  (OX)-induced  allergic  dermatitis  mouse 
models, and importantly, combination therapy of PPARα agonists and GCs for 
severe  dermatitis  prevented  GC-induced  side  effects  and  inhibited  rebound 
flares  (Sheu  et  al.,  2002;  Hatano  et  al.,  2011).  Conversely,  activation  of 
PPARβ/δ  may  trigger  psoriasis  pathogenesis  within  the  skin  and  treatment 
strategies  may  include  antagonism  of  this  signaling  pathway.  PPARβ/δ  is 
upregulated at both the mRNA and protein level in psoriatic lesions compared 
to nonlesional skin in human patients and eicosanoid accumulations within the 
lesions can activate PPARβ/δ (Westergaard et al., 2003; Romanowska et al., 
2010). Also, topical antagonists targeted to cutaneous PPARβ/δ demonstrated 
efficacy  in  a  psoriatic  mouse  model  (Hack  et  al.,  2012).  Alongside  other 
physiological  defects,  PPARβ/δ-null  mice  exhibit  an  elevated  epidermal 
hyperplastic response after TPA administration and delayed barrier recovery 
following acute barrier disruption (Peters et al., 2000; Man et al., 2008). An 
increase  in  the  release  of  inflammatory  cytokines  after  wound  healing  in   18 
 
murine skin requires upregulation of PPARβ/δ that is otherwise undetected in 
normal skin. Interestingly, this pro-inflammatory cascade initiates production of 
endogenous PPARβ/δ ligands, reinforcing the activation of PPARβ/δ after skin 
injury  (Tan  et  al.,  2001;  Tan  et  al.,  2005).  PPARβ/δ  is  also  linked  to  UV-
induced  premature  senescence  via  upregulation  of  PTEN  that  attenuates 
reactive  oxygen  species  in  keratinocytes  (Ham  et  al.,  2012).  Likewise, 
epidermal PPARγ signaling is also a target for the UV-induced inflammatory 
response.  UV  irradiation  of  human  keratinocytes  produces  potent  PPARγ 
agonistic activity and enhances COX-2 expression in these cells. Furthermore, 
PPARγ activation was seen as a general consequence to various oxidative 
stressors in human sebocytes (Zhang et al., 2005; Zhang et al., 2006). 
   An  increased  accessibility  of  environmental  antigens  through  epidermal 
tissue can activate cutaneous immune responses that potentially drive these 
syndromes.  Creation  and  maintenance  of  the  EPB  is  a  multistep  process 
involving  lipid  production  and  lamellar  body  formation  and  LXR  activation 
appears to hold key functions in many of these stages (Fluhr et al., 2005; Man 
et al., 2006). EPB function is tightly linked to cholesterol levels in the epidermis 
and LXR has been shown to regulate the storage and efflux of lipid species. 
Members of the ATP-binding cassette transporter family, as well as glycerol 
channels,  are  transcriptionally  regulated  by  oxysterols  (Jiang  et  al.,  2006; 
Jiang et al., 2008; Jiang et al., 2010; Jiang et al., 2011). Environmental toxins   19 
 
present in cigarette smoke have been linked to several skin diseases such as 
psoriasis and melanoma. Translocation of LXR to the nucleus in HaCaT cells 
after  exposure  to  cigarette  smoke  facilitated  an  increase  in  cholesterol 
trafficking as a result of increased ABCA1 expression (Sticozzi et al., 2010). 
The ability of the synthetic LXR agonist T1317 to prevent physical changes 
inherent to photoaging and chronological skin aging has been investigated. 
T1317  inhibited  the  expression  of  cytokines  and  metalloproteinases  in  cell-
based models of skin aging. Furthermore, LXRβ-null
 murine skin mimics some 
of  the  characteristics  seen  in  chronologically  aged  human  skin  and  the 
topically  applied  agonist  reduced  UV-induced  skin  thickness  and  wrinkle 
formation in a mouse model (Chang et al., 2008).  
   The anti-inflammatory actions of LXR activators have been demonstrated in 
both irritant and oxazolone (OX)-induced allergic dermatitis mouse models, in 
part  through  the  inhibition  of  proinflammatory  cytokines  that  are  specific  to 
LXRβ (Fowler  et  al.,  2003;  Hatano  et  al.,  2010).  Similarly,  global  gene 
expression studies using primary human keratinocytes from psoriatic lesions, 
non-affected skin of the same patients and healthy control subjects, indicates 
a  role  for  LXRα  in  regulating  inflammatory  response.  Along  the  same  line, 
knocking down LXRα in human keratinocytes lead to a genomic profile similar 
to that seen in psoriatic skin lesions (Gupta et al., 2010). Even if LXRs are not 
directly involved in disease pathogenesis, the receptors might still be utilized   20 
 
as therapeutic tools to modulate cellular lipid levels. For example, a human 
sebaceous cell line treated with LXRα agonists increased lipid synthesis and 
induced the lipogenic gene SREBP-1, potentially useful for the treatment of 
seborrhea  and  acne  (Hong  et  al.,  2008).  Selective  LXR  agonists  that  are 
isoform  and  tissue-specific  could  provide  localized  and  specific  cutaneous 
effects that do not influence other LXR receptor pools (Bookout et al., 2006; 
Viennois et al., 2012). 
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1.5  Epidermal carcinogenesis 
 
   Non-melanoma skin cancers arise from both the basal and squamous cells 
of the epidermis. Basal cell carcinoma (BCC) is the most common neoplasm 
related to the Caucasian population and its incidence rate is increasing yearly 
(Diepgen and Mahler, 2002). Though considered malignant due to its ability to 
invade deep into tissue, it rarely metastasizes from the primary location. Risk 
factors  include  fair  skin  disposed  to  freckling,  family  history  of  BCC  and 
exposure to ultraviolet radiation. Patients with BCC also tend to be prone to 
other types of skin cancer including malignant melanoma (Wong et al., 2003). 
Disease  progression  typically  arises  from  UV-induced  actinic  keratosis  or 
mutations  in  the  hedgehog  signaling  pathway.  Surgical  excision  is  the 
treatment of choice though pathway specific compounds such as vismodegib 
provide additional therapy options (Sekulic et al., 2012). Cutaneous squamous 
cell carcinoma (SCC) is the second leading cause of skin cancer, yet unlike 
BCC  it  tends  to  exhibit  metastatic  behavior  (Johnson  et  al.,  1992).  Again, 
exposure to ultraviolet radiation is the predominant risk factor for this disease, 
though immunosuppressed patients are at increased risk for metastatic spread 
(Rowe  et  al.,  1992).  Treatment  options  include  surgical  removal,  radiation 
therapy  and  in  certain  cases  chemotherapeutics  such  as  5-fluorouracil  or 
imiquimod  (Love  et  al.,  2009).  Investigations  into  pathways  regulating   22 
 
keratinocytic proliferation and differentiation may lead to additional treatment 
options useful in treating these disfiguring diseases. 
   The transcription factor KLF4 is required for proper EPB formation in mice 
and dysregulated KLF4 activity is shown to be oncogenic (Segre et al., 1999). 
KLF4  regulates  expression  of  RXRα  and  KLF4-induced  malignant 
transformation is sensitive to retinoids in vitro. Importantly, rexinoid application 
drastically prevented formation of SCC in a KLF4-activated transgenic mouse 
line  (Jiang  et  al.,  2009).  These  results  suggest  existence  of  a  crosstalk 
between RXR and KLF4 signaling, where KLF4-mediated expression of RXRα 
contributes to tumor suppressor activity within the epidermis. RXRα
ep-/- mice, 
selectively  lacking  RXRα  in  epidermal  keratinocytes,  subjected  to  a  7,12-
dimethylbenz(a)anthracene  (DMBA)/12-O-tetradecanolyphoral-13-acetate 
(TPA)  induced  two-step  chemical  carcinogenic  protocol  developed  higher 
numbers of epidermal tumors compared to control mice (Indra et al., 2007). 
The RXRα
ep-/- papillomas progressed towards SCC in a murine model, further 
validating the role of RXRα as a cutaneous tumor suppressor. 
   Both  keratinocytes  and  melanocytes  downregulated  expression  of  RARs 
when  subjected  to  UV  exposure,  potentially  initiating  cellular  responses  to 
ionizing  radiation  through  the  removal  of  repressive  transcriptional  controls 
(Wang et al., 1999; Boudjelal et al., 2000; Andersson et al., 2003). A similar 
downregulation of RAR in mouse skin was seen after application of TPA, as   23 
 
well  as  when  normal  human  skin  progresses  through  premalignant  actinic 
keratosis to invasive SCC (Kumar et al., 1994; Darwiche et al., 1995; Xu et al., 
2001). A loss of RARγ expression exacerbated carcinogenic effects of tumor 
promoters and enhances malignant transformation (Rudd et al., 1993; Chen et 
al., 2004). Topical application of RA during the promotion stage of carcinogen 
treatment  in  mice  reduced  the  yield  of  papilloma  and  carcinoma  formation 
(Tennenbaum et al., 1998). Likewise, the RARβ/γ retinoid tazarotene displayed 
anti-tumoral activity when topically applied to BCC and may inhibit psoriatic 
proinflammatory gene networks (Nagpal et al., 1996; Orlandi et al., 2004; So 
et al., 2008). Above results indicate important roles of retinoids and retinoid 
receptors in the control of epidermal homeostasis and prevention of hyper-
proliferative diseases and skin cancer.  
   The regulatory nature of VDR in hair cycle progression and barrier formation 
is critical to maintain skin homeostasis, therefore defects in the transactivating 
function of the receptor allow pathological conditions to manifest. Multiple VDR 
polymorphisms  have  been  associated  with  a  broad  spectrum  of  cutaneous 
disease,  including  SCC,  BCC  and  vitiligo (Han  et  al.,  2007;  Carless  et  al., 
2008; Raimondi et al., 2009; Lesiak et al., 2011; Kostner et al., 2012; Aydingoz 
et al., 2012). Indeed, inactivation of VDR in mice enhanced sensitivity to both 
chemical and solar-induced skin carcinogenesis, potentially through activation 
of the hedgehog pathway (Ellison et al., 2008; Teichert et al., 2011).   24 
 
   Due to evidence of PPAR signaling in the development of aberrant growths 
in differing tissue types, studies have investigated the role of these receptors 
in  cutaneous  neoplasms.  Tumor  formation  and  size  were  increased  after 
chemical  carcinogen  application  in  PPARβ/δ
-/-  mice,  while  those  selectively 
lacking PPARγ in epidermal keratinocytes show an increase in benign tumors, 
SCC  and  BCCs  (Indra  et  al.,  2007;  Kim  et  al.,  2004).  Ligand  activation  of 
PPARβ/δ inhibits chemically induced skin tumorigenesis, most likely through 
induction of keratinocytic differentiation, and the addition of COX-2 inhibitors 
may result in synergistic efficacy (Bility et al., 2008; Zhu et al., 2010). 
   In mice, TRβ expression is detected in normal and TPA-treated hyperplastic 
skin. Loss of TRβ expression is seen in benign papillomas generated by the 
DMBA/TPA protocol and completely abrogated in subsequent SCC formation. 
Importantly, skin tumors from mice lacking both TRα and TRβ were more likely 
to  develop  in  situ  carcinoma  and  SCC  than  those  from  wildtype  mice, 
supporting TRs role as a tumor suppressor (Martinez-Iglesias et al., 2009). In 
order  to  determine  the  role  TRs  have  in  the  hyperproliferative  response, 
TRα/β-double  null  mice  were  subjected  to  both  TPA  and  RA  treatments 
(Contreras-Jurado  et  al.,  2011;  Garcia-Serrano  et  al.,  2011).  Reduced 
hyperplasia with a decreased expression of cyclin D1 was seen in the TRα/β
-/- 
skin  after  TPA  treatment.  That  profile  was  correlated  with  increases  in  cell 
cycle inhibitors p19 and p27, as well as induction of proinflammatory cytokines   25 
 
and phosphorylation of p65/NF-κB and STAT3. This phenotype is opposite to 
that  seen  in  PPARβ/δ
-/-  mice  and  elucidates  the  combinatorial  mechanisms 
RXR/NR  heterodimers  regulate  within  the  skin.  Similarly,  a  typical  retinoid 
response requires the presence of ligand-bound TR in mouse skin. Decreases 
in  skin  hyperplasia  and  expression  of  keratins  5/6,  alongside  increased 
transcription  of  inflammatory  and  chemotactic  cytokines,  are  also  seen  in 
TRα/β
-/- mice treated with 9-cis RA. Since TPA and retinoids are modulating 
separate signaling cascades, it is possible that TRs are involved in the cellular 
responses to both these compounds.   26 
 
1.6  Melanocyte homeostasis and melanomagenesis 
 
   Melanocytes are neural crest-derived pigment producing cells that contribute 
photoprotective properties to the skin. Cutaneous melanoma is the deadliest 
form  of  skin  cancer,  with  a  diagnosis  of  metastasis  indicating  a  median 
survival rate of less than a year (Chin et al., 2006). Solar ultraviolet irradiation, 
especially  childhood  sun  exposure,  is  an  important  etiological  risk  factor  of 
melanoma  (Hodis  et  al.,  2012).  Surgical  excision  prevents  growth  of  the 
primary lesion, yet once transformed melanocytes spread to distal organs and 
this disease is refractory to current therapeutics. Recent evidence supports the 
use of MAPK inhibitors and immunomodulatory treatments with the goal of 
increasing lifespan (Flaherty et al., 2010, Hodi et al., 2010). Therefore, any 
research  directed  towards  key  regulators  of  melanocytic  activity  could 
potentially open up new avenues for disease management. 
   Type  II  NR-mediated  signaling  via  RXR  dimerization  is  essential  to 
melanocyte biology. RXRα/β expression has been detected in B16 and S91 
murine melanoma cells, with RXRβ being the predominant isoform (Desai and 
Niles, 1995; Spanjaard et al., 1995). Interestingly, loss of melanocytic RXRα 
expression was seen in human primary and metastatic melanoma compared 
to  benign  nevi,  indicating  the  importance  of  this  signaling  pathway  to  the 
differentiation of these cell types (Chakravarti et al., 2007). RARβ expression   27 
 
was  also  downregulated  in  melanoma  and  its  RA-induced  expression  was 
linked  to  growth  inhibition  and  differentiation  in  these  cells.  Sequential 
occupation  of  the  RA  response  element  located  on  the  Rarβ  promoter  by 
RXR/RXR and RXR/RAR combinations is believed to be a molecular switch 
responsible  for  Rarβ  transcriptional  activation  in  these  cells.  Since  ligand 
activation of RXR heterodimeric partners regulates transcriptional activity of 
target genes involved with differentiation and growth arrest, it is possible that 
combinatorial  activation  of  both  dimer  partners  may  assist  in  melanoma 
therapy.  Rexinoid  treatment  alongside  glitazones  (PPARγ  agonists)  have 
displayed efficacy against melanomagenesis in in vitro and xenograft models, 
potentially through the inhibition of matrix metalloproteases and increases in 
S100A2  calcium  binding  activity  (Papi  et  al.,  2009;  Klopper  et  al.,  2009; 
Klopper et al., 2010). 
   Our  own  work  has  demonstrated  the  role  of  keratinocytic  RXRα  in 
manipulating melanocyte activation and proliferation through modulation of the 
cutaneous  microenvironment  (Wang  et  al.,  2011).  RXRα/NR  heterodimer 
binding regulates transcriptional repression of soluble mitogens and cytokines, 
making  it  a  critical  factor  in  the  ultraviolet  radiation  (UVR)  induced  cellular 
responses.  The  loss  of  keratinocytic  RXRα  in  RXRα
ep-/-  mice  relieves 
transcriptional repression and allows overexpression of keratinocytic soluble 
factors  that  act  on  melanocytic  cell-surface  receptors.  Higher  numbers  of   28 
 
epidermal  melanocytes  were  seen  after  UVR  exposure  in  RXRα
ep-/-  mice 
compared to controls, suggesting contribution of soluble factors in the cellular 
microenvironment  for  melanocyte  activation  and  migration  out  of  the  hair 
follicle. Indeed, increased expression of Edn1, Fgf2 and Kitlg, that are known 
to  be  upregulated  by  keratinocytes  and  influence  melanocyte  activation, 
migration and proliferation, were seen in RXRα
ep-/- skin post-UVR (Wang et al., 
2011).  Interestingly,  in  a  two-step  carcinogenesis  model,  RXRα
ep-/-  mice 
developed a higher number of dermal melanocytic growths (nevi) compared to 
control  mice,  implicating  contribution  of  keratinocyte-derived  factors  in 
melanomagenesis.  Only  nevi  from  RXRα  mutant  mice  progressed  to 
melanoma-like  tumors,  suggesting  that  RXRα-mediated  distinct  non-cell 
autonomous actions suppressed nevi formation and melanoma progression in 
mice (Indra et al., 2007). Similarly, VDR
-/- mice undergoing identical treatments 
also developed higher numbers of melanocytic lesions, indicating RXRα/VDR 
heterodimerization may be the causative factors, at least in part, in these non-
cell autonomous events (Indra et al., 2007). Finally, the loss of keratinocytic 
RXRα  alongside  an  activated-CDK4  mutation  enhanced  the  metastatic 
transformation  of  cutaneous  melanoma  after  chemical  carcinogenesis. 
Expression of Edn1, Hgf, Fgf2, Pomc and Kitlg were all upregulated in the skin 
of  RXRα
ep-/-/CDK4
R24C/R24C  bigenic  mice.  Direct  binding  of  RXRα  on  the 
promoter  of  Edn1  and  Hgf  was  also  seen  in  ex  vivo  primary  murine   29 
 
keratinocytes. Gene expression analyses on mRNA isolated from melanocytic 
lesions  from  the  bigenic  skin  using  laser-capture  microdissection 
demonstrated  reduced  apoptotic  and  enhanced  invasive  responses  within 
bigenic  melanomas.  Loss  of  epidermal  RXRα was  also  seen  in  human 
melanoma  progression  and  could  potentially  be  utilized  as  a  therapeutic 
biomarker  (Hyter  et  al.,  2010).  These  results  indicated  a  crucial  role  of 
RXRα/NR signaling in melanocytic homeostasis and in cellular responses to 
tumor promotion. 
   All RAR isoforms were expressed in melanocytes and treatment of retinoids, 
particularly RARγ-specific agonists, inhibits growth and initiates apoptosis in 
melanoma  cells  (Schadendorf  et  al.,  1994;  Zhang  et  al.,  2003;  Pan  et  al., 
2009).  RA  treatment  increases  expression  of  RARβ  and  PKCα  while 
stimulating  AP-1  transcriptional  activity  in  melanoma  cells.  RARα  specific 
agonists were most effective in upregulating RARβ levels and combinatorial 
RAR/RXR activation demonstrate the strongest induction of both PKCα and 
AP-1 function in murine melanoma cells (Desai et al., 2000; Boskovic et al., 
2002;  Huang  et  al.,  2003).  Loss  of  RARs,  especially  RARβ  and  its  tumor 
suppressor  activities,  was  observed  during  melanomagenesis  and  could 
account for RA resistance in this disease (Chakravarti et al., 2007; Boehm et 
al.,  2004;  Fan  et  al.,  2010).  That  disruption  of  RARβ  or  RARγ  signaling  in 
benign nevi may predispose a lesion towards malignant transformation. Co-  30 
 
treatment  of  retinoids  with  histone  deacetylases  also  counteracted  the 
epigenetic silencing of RARβ often seen in RA resistant melanoma cell lines 
and  provides  increased  antitumor  activity  (Kato  et  al.,  2007).  Another 
mechanism  implicated  in  RA-resistant  melanoma  cells  is  an  increase  in 
intracellular reactive oxygen species (ROS) that is inversely related to RAR 
activity.  RA-sensitivity  was  restored  when  ROS  levels  were  lowered, 
potentially through improved RXR/RAR promoter binding activity (Demary et 
al., 2001). RA treatment in combination with polyl:C synergistically increased 
the toll-like receptor 3 chemokine responses in human melanoma cells and 
induced migration of antigen-presenting cells (Szabo et al., 2012). Decreased 
expression  of  collagenolytic-enzymes  and  alterations  in  mobility-associated 
cell  surface  receptors  were  consequences  of  RAR  activation  in  melanoma 
cells  (Hendrix  et  al.,  1990;  Lee  et  al.,  2010).  Further  evidence  of  RARγ-
mediated inhibition of melanoma invasion came from microarray analysis of 
murine  melanoma  cells  treated  with  RARγ  agonists,  which  identified  the 
sulfotransferase  CHST10  as  being  directly  regulated  by  RARγ  through  RA 
response  elements  located  in  its  promoter  region.  CHST10  synthesizes  a 
HNK-1  carbohydrate  that  was  involved  with  cell  adhesion  in  the  nervous 
system and RA-mediated embryonic plasticity (Zhao et al., 2009). Altogether, 
RAR-specific  agonists  present  a  potential  therapeutic  candidate  for  the   31 
 
treatment  of  metastatic  melanoma  if  mechanisms  of  RA  resistance  can  be 
elucidated and exploited. 
   Skin is both a target and producer of 1,25(OH)2D3, the secosteroid ligand of 
VDR and regulation of melanocyte homeostasis is a physiological role that is 
attributed to VDR signaling. The use of vitamin D analogs to combat vitiligo 
depigmentation has been well reviewed (Birlea et al., 2008). It is hoped that 
Vitamin  D  agonists  might  protect  melanocyte  loss  in  this  disease  through 
inhibition of immune response and modulating calcium flux. VDR activation 
may  also  promote  re-pigmentation  processes  by  upregulating  melanogenic 
cytokines that drive pigment production. Due to insufficient knowledge on what 
drives the etiology of this disease, any research implicating driver mutations is 
important for developing effective therapeutics. Genomic DNA isolated from 
vitiligo patients, as well as age and sex-matched controls, demonstrated the 
TaqI  VDR  polymorphism  is  a  risk  factor  for  the  disease.  Haplotype 
BsmI/ApaI/TaqI/FokI/Cdx2  was  also  overrepresented  in  those  patients 
(Aydingoz et al., 2012).  
   The use of low-calcemic deltanoids for treatment of melanocytic lesions is 
another  potential  candidate  for  future  therapies.  Sunlight  generates  DNA 
damage within melanocytes yet also produces anti-proliferative 1,25(OH)2D3 
ligands.  This  physiological  dichotomy  provides  endogenous  regulation  of 
melanomagenesis  and  may  offer  directions  on  how  to  manage  cutaneous   32 
 
melanoma. Human melanoma cell lines have been shown to posses different 
expression  levels  of  VDR  and  different  growth  inhibitory  responses  to 
1,25(OH)2D3. Importantly, melanoma cells demonstrate increased sensitivity to 
deltanoids compared to normal melanocytes (Slominski et al., 2011). Similar to 
some  other  type  II  NRs,  a  loss  of  VDR  expression  was  seen  during  the 
progression  of  melanocytic  lesions  and  that  attenuated  VDR  signaling  was 
linked to decreased overall survival time (Brozyna et al., 2011). Likewise, a 
retrospective cohort study of large numbers of melanoma patients associated 
higher  serum  1,25(OH)2D3  levels  with  thinner  presenting  melanomas  and 
improved survival from melanoma (Newton-Bishop et al., 2009). In addition to 
investigations  associating  VDR  polymorphisms  to  keratinocytic  pathologies, 
extensive studies have shown VDR mutations as a critical contributing factor 
towards  melanoma  susceptibility  and  outcome,  in  particular  the  BsmI,  FokI 
and  TaqI  polymorphisms  (Denzer  et  al.,  2011;  Mandelcorn-Monson  et  al., 
2011;  Orlow  et  al.,  2012).  Not  all  melanoma  cell  lines  were  sensitive  to 
1,25(OH)2D3 treatment though. Resistance to 1,25(OH)2D3 treatment may be 
attributed to epigenetic mechanisms that abrogate VDR signaling in those cell 
lines. An inverse relationship has been shown to exist between VDR mRNA 
expression  and  level  of  microRNA  miR-125b,  most  likely  through 
posttranscriptional  regulation  of  VDR  by  miR-125b  interacting  with  a 
recognition element in the 3ʼ-UTR of human VDR mRNA. Treatment of these   33 
 
cells with a DNA methyltransferase inhibitor reduces expression of miR-125b 
and may prove efficacious alongside other chemical therapies (Essa et al., 
2010;  Essa  et  al.,  2012).  In  short,  aberrant  VDR  signaling  appears  to 
contribute  significantly  to  the  development  of  melanoma  in  humans  and 
1,25(OH)2D3  analogs  may  provide  additional  targeted  chemotherapeutics  in 
the treatment of that disease. 
   Due to importance of lipid metabolism in skin homeostasis, PPAR signaling 
in  skin  has  been  thoroughly  investigated,  including  its  role  in  melanocyte 
homeostasis.  All  PPAR  isoforms  are  expressed  in  human  melanocytes, 
though  PPARγ  signaling  appears  to  be  a  primary  possible  drug  target  for 
melanoma. Two common PPARγ polymorphisms implicated in susceptibility of 
the malignant disease were evaluated as influences in melanoma risk, though 
it appeared that inactivating mutations do not appear to be a significant risk 
factor  for  the  disease  (Mossner  et  al.,  2007).  Recently  a  link  was  shown 
between  α-MSH  signaling  and  PPARγ  nuclear  translocation  that  reduced 
proliferation  rates  and  increased  melanogenesis  through  the  Pi(4,5)P2/Plcb 
pathway (Maresca et al., 2012). Glitazones are known to activate PPARγ and 
promote  melanocyte  differentiation.  One  mechanism  to  induce  melanocyte 
differentiation  is  through  b-catenin  mediated  upregulation  of  MITF  levels. 
Phenotypic changes that occured in melanoma cells post-ciglitazone treatment 
include  dendritic  morphology  and  increased  tyrosinase  functions,  possibly   34 
 
linked to large increases of Mitf promoter activity. β-catenin protein levels in 
ciglitazone-treated murine melanoma cells followed the same trend of transient 
increase followed by gradual decrease pattern as seen with MITF, suggesting 
that depleted levels of nuclear β-catenin was influencing the downregulation of 
MITF  activity  in  these  cells  (Grabacka  et  al.,  2008).  In  addition  to  its  pro-
differentiative properties, inhibition of proliferation was seen in melanoma cells 
after ciglitazone treatment and is also associated with induction of apoptosis 
(Liu  et  al.,  2006).  PPARγ  agonists  regulate  the  WNT3A/β-catenin  signaling 
pathway  and  inhibits  human  melanoma  cell  proliferation  through  direct 
inhibition of β-catenin activity (Smith et al., 2009). Though PPAR functions as 
a  tumor  suppressor  at  times,  two  studies  screening  large  numbers  of 
melanocytic lesions determined that both PPARγ and COX-2 expression was 
increased during progression from benign nevi to metastatic melanoma and 
may indicate therapy response levels of this disease (Lee et al., 2008; Meyer 
et al., 2009). That conflicting role of PPARγ in tumorigenesis has yet to be 
elucidated  but  provides  an  exciting  investigative  target  in  the  treatment  of 
metastatic melanoma.  
   Few reports demonstrate a role of LXR activation in melanocytes, though 
known LXR target genes are important in melanocyte biology. LXRα appears 
to be the predominant isoform and could provide LXR-oriented strategies of 
melanoma  therapy.  LXRα  expression  was  also  localized  adjacent  to  the   35 
 
follicular dermal papilla, suggesting a contribution to hair follicle melanocyte 
activity  (Russell  et  al.,  2007).  LXRα  expression  was  seen  in  both  human 
melanocytes  and  in  melanoma  cells.  Moreover,  LXRα  mRNA  and  protein 
levels were increased in melanocytes present in the skin surrounding vitiligo 
lesions  compared  to  normal  skin,  suggesting  LXRα  is  modulating  the 
melanocytic response to this disorder (Chen et al., 2005; Kumar et al., 2010). 
Interestingly, LXRα has been linked to immunoevasion of melanoma through 
inhibition  of  dendritic  cell  (DC)  migration  to  lymphoid  organs.  Production  of 
LXR ligands from both human and mouse tumors were shown to hinder CCR7 
expression on DCs that is required for lymphoid homing. Conditioned media 
from  the  human  melanoma  cell  line  MSR3  was  shown  to  inhibit  CCR7 
expression in DCs, though not affecting other aspects of DC activation. Also, 
the media from MSR3, as well as from another melanoma cell line MR255, 
was  able  to  activate  LXRα reporter  constructs,  suggesting  the  presence  of 
ligands  expressed  in  the  media.  Use  of  the  sulfotransferase  enzyme 
SULT2B1b, which inactivates natural oxysterols, was able to protect CCR7 
inhibition from the conditioned media. Similarly, mice receiving bone marrow 
transplants from an LXRα-null line demonstrated an enhanced ability of tumor 
rejection (Villablanca et al., 2010). Altogether, studies indicate an important 
immuno-modulatory  role  of  LXR  signaling  in  melanocytic  lesions  and  in 
melanoma  primarily  mediated  by  LXRα.  Additional  studies  are  required  to   36 
 
establish  the  receptor  functions  in  melanocyte  homeostasis  and  in 
melanomagenesis. 
   Evidence for a role of TR in melanocyte biology is limited, though thyroid-
stimulating hormone expression is seen in epidermal melanocytes. Of note, 
one study involving patients with uveal melanoma demonstrated that 60% of 
the cohort contained a loss of heterozygosity in the TRβ alleles in both the 
ciliary  body  and  choroidal  melanomas  (Sisley  et  al.,  1993).  Further  in  vivo 
studies are needed to determine how TR signaling is impaired in epidermal 
diseases and in skin cancer, as well as the severity of any non-autonomous 
actions that affect the malignant transformation of melanocytic cells. 
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1.7  Conclusion 
 
   RXR/NR signaling makes important contributions to both the development 
and  homeostasis  of  keratinocyte  and  melanocyte  biology.  The  ability  of 
epidermal tissue to maintain a rigorous cycle of proliferation and differentiation 
utilizes complex transduction pathways that rely on tight transcriptional control 
of key target genes. Ligand activated regulation of gene transcription and/or 
repression by type II NR heterodimers is one example of how skin is able to 
continually  replenish  itself  while  at  the  same  time  inhibiting  neoplastic 
transformation. Extensive research presents a scenario where type II NRs are 
critical  tumor  suppressors  that  regulate  the  sequential  differentiation  of 
maturing keratinocytes. With the exception of TR, which does not appear to 
play a major role in skin biology, loss of RXR/NR activity through inactivating 
mutations  or  epigenetic  silencing  leads  to  hyperproliferation  and  immune 
responses.  Likewise,  activation  of  NR  heterodimers  through  endogenous 
ligand binding, or exogenous topical application of synthetic agonists, typically 
provides  anti-inflammatory  actions.  Modulation  of  these  receptors  could 
provide  supplemental  therapy  for  inflammatory  skin  disease  that  is  usually 
treated with potent GCs. The development of tissue specific NR ligands may 
provide additional relief for diseases such as psoriasis and AD that are not 
currently curable. RXR/VDR regulation of genes such as TSLP provides strong   38 
 
drug targets that could significantly alter the micro-environmental milieu that 
drives skin inflammation. Abolishing keratinocytic derived paracrine signaling 
utilized by melanocytes and immune cells may provide additional options in 
curative techniques for skin diseases including melanoma. Overall, RXR/NR 
signaling has evolved as extensive and dominant signaling networks within 
skin, the largest organ and most important barrier to environmental damages 
and insults. Utilizing these regulatory checkpoints through the use of synthetic 
ligands  will  be  an  important  focus  of  cutaneous  research  in  the  immediate 
future. 
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Figure  1.1  Schematic  representation  of  functional  domains  in  type  II 
nuclear  receptors.  Transcriptional  activation  function  1  (AF-1)  domain 
initiates at the amino terminus, followed by the DNA-binding domain (DBD). A 
flexible  hinge  region  (H)  assists  in  DNA  binding,  dimerization  and 
transactivation functions. Variable ligand-binding domains (LBD) and a second 
activation  function  (AF-2)  are  present  at  the  carboxyl  terminus.  60 
 
 
 
 
 
 
 
Figure 1.2 Putative mechanisms of transcriptional regulation by type II 
nuclear  receptors.  Repression  of  gene  expression  by  nuclear  receptor 
heterodimers  involves  association  with  co-repressor  protein  complexes, 
including  NCoR/SMRT  and  histone  deacetylases  (HDAC).  Positive 
transactivation  occurs  when  co-repressor  complexes  are  replaced  by  co-
activator  proteins  such  as  ATP-dependant  chromatin  remodelers  (ADCR), 
histone acetyltransferases (HAT) and the Mediator complex (MC). DBD, DNA-
binding  domain;  LBD,  ligand-binding  domain;  NRRE,  nuclear  receptor 
response element; TSS, transcriptional start site. 
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2.1  Abstract 
 
   Keratinocytes  contribute  to  melanocyte  transformation  by  affecting  their 
microenvironment, in part, through the secretion of paracrine factors. Here we 
report  a  loss  of  expression  of  nuclear  receptor  RXRα  in  epidermal 
keratinocytes during human melanoma progression. We show that absence of 
keratinocytic RXRα in combination with activated CDK4 generated cutaneous 
melanoma  that  metastasized  to  lymph  nodes  in  a  bigenic  mouse  model. 
Expression  of  several  keratinocyte-derived  mitogenic  growth  factors  (Edn1, 
Hgf, Kitlg, α-Msh and Fgf2) were elevated in skin of bigenic mice, while FAS, 
E-cadherin  and  PTEN,  implicated  in  apoptosis,  cellular  invasion  and 
melanomagenesis,  respectively,  were  downregulated  within  the 
microdissected melanocytic tumors. We demonstrated that RXRα is recruited 
on the proximal promoter of both Edn1 and Hgf, possibly directly regulating 
their transcription in keratinocytes. These studies demonstrate the contribution 
of  keratinocytic  paracrine  signaling  during  the  cellular  transformation  and 
malignant conversion of melanocytes.   63 
 
2.2  Introduction 
 
   Cutaneous  melanoma  remains  the  deadliest  form  of  skin  cancer.  Early 
detection can lead to effective treatment, but metastatic melanoma is typically 
non-responsive  to  current  therapies  and  the  median  time  of  survival  for 
patients  is  less  than  a  year  (Chin  et  al.,  2006).  Melanoma  originates  from 
pigment-producing cells in the skin called melanocytes that play a role in the 
epidermal response to UV radiation. In recent years, animal models that mimic 
genetic aberrations linked to melanomagenesis in humans have led toward a 
better  understanding  of  underlying  molecular  mechanisms  (Larue  and 
Beermann, 2007). 
   Keratinocytes encompass and support the skin epidermal layer through a 
constant  cycle  of  proliferation  and  differentiation.  Epidermal  proliferation  is 
regulated  through  secretion  of  keratinocytic  autocrine  growth  factors  that 
influence  receptor-mediated  signals  within  the  cell (Cook  et  al.,  1991).  The 
transfer of melanin from melanocytes to keratinocytes aids in the prevention of 
UV-induced genetic mutations and requires interaction between these two cell 
types (Scott, 2006). Communications between melanocytes and keratinocytes 
rely upon paracrine signaling that utilize soluble factors such as endothelin 1 
(EDN1),  fibroblast  growth  factor  2  (FGF2),  Kit  ligand  (KITLG),  alpha-
melanocyte  stimulating  hormone  (α-MSH)  and  hepatocyte  growth  factor 
(HGF); all of which have been shown to influence melanocyte mitogenesis,   64 
 
melanogenesis, and melanomagenesis (Cui et al., 2007; Halaban et al., 1988; 
Halaban et al., 1992; Hirobe, 2005; Imokawa et al., 1992; Kunisada et al., 
1998).  Aberrant  paracrine  signaling  might  result  in  the  transformation  of 
melanocytes to malignant cells (Mangahas et al., 2004; Otsuka et al., 1998).   
   The  steroid  hormone  receptor  protein  retinoid-X-receptor  α  (RXRα),  a 
member of the type II nuclear receptor (NR) superfamily, mediates biological 
effects in part through the regulation of gene transcription. RXRα is able to 
heterodimerize with some 15 NR family members and occupy corresponding 
response elements present in the promoters of target genes (Chambon, 1996; 
Mangelsdorf  et  al.,  1995).  RXR/NR  heterodimerization  modulates  gene 
transcription  (activation  and/or  repression),  and  acts  on  multiple 
developmental and differentiation processes (Altucci and Gronemeyer, 2001).  
   Three  subtypes  of  the  RXR  protein  are  present  in  mammals,  with  RXRα 
being  the  predominant  form  expressed  in  murine  epidermis  (Fisher  and 
Voorhees,  1996;  Mangelsdorf  et  al.,  1992).  The  RXRα-null  mutation  is 
embryonic lethal in mice, thereby preventing analysis of in vivo function of this 
protein in skin homeostasis and diseases (Sucov et al., 1994; Kastner et al., 
1994).  To  circumvent  this  problem,  Cre/loxP  technology  was  utilized  to 
selectively delete the RXRα protein in epidermal keratinocytes (Metzger et al., 
2003). The RXRα
ep-/- mouse line displayed alopecia, epidermal keratinocytic 
hyperproliferation,  aberrant  terminal  differentiation  and  an  inflammatory   65 
 
reaction within the skin (Li et al., 2001). In a two-step chemical carcinogen 
model  using  topical  applications  of  the  tumor  initiator  7,  12-dimethyl-
benz[a]antracene (DMBA) and tumor promoter 12-O-tetradecanoylphorbol-13 
acetate  (TPA),  RXRα
ep-/-  mice  developed  a  higher  number  of  dermal 
melanocytic growths (nevi) compared to control mice. Only nevi from RXRα 
mutant  mice  progressed  to  human-melanoma-like  tumors,  suggesting  that 
RXRα-mediated  distinct  non-cell  autonomous  molecular  events  appear  to 
regulate suppression of nevi formation and melanoma progression (Indra et 
al., 2007). Of note, the tumors that formed in RXRα
ep-/- mice after DMBA/TPA 
treatment rarely invaded or metastasized to distal organs. 
   Cyclin-dependent kinase 4 (CDK4) protein, a product of the Ink4a locus, has 
been  implicated  in  the  development  of  cutaneous  melanoma  (Curtin  et  al., 
2005; Kamb et al., 1994). An arginine to a cysteine point mutation in the CDK4 
protein found in familial melanoma (CDK4
R24C/R24C) prevents the kinase activity 
of CDK4 from being inhibited by the G1/S phase regulator p16, leading to an 
increase  in  cell-cycle  activity  (Wolfel  et  al.,  1995;  Zuo  et  al.,  1996). 
CDK4
R24C/R24C  knock-in  mice  harboring  this  activated  form  of  CDK4 
demonstrated  increased  susceptibility  to  melanoma  formation  after 
DMBA/TPA treatment (Rane et al., 1999; Sotillo et al., 2001). Mice containing 
the CDK4
R24C/R24C mutation in cooperation with deregulated receptor tyrosine 
kinase signaling, or activated RAS, has been shown to promote development   66 
 
of spontaneous and carcinogen-induced metastatic melanoma (Hacker et al., 
2006; Tormo et al., 2006).  
   In this study, we evaluated expression of RXRα protein in normal human 
skin, tumor adjacent normal, benign nevi, in situ and malignant melanoma. We 
investigated  the  contributions  of  CDK4
R24C/R24C  and  keratinocytic  RXRα  to 
influence  metastatic  progression  in  a  mouse  model.  Expression  of  several 
keratinocyte-derived  growth  factors,  implicated  in  melanomagenesis,  were 
upregulated in the skin of bigenic mice, and recruitment of RXRα was shown 
on the promoters of Edn1 and Hgf. We also confirmed a downregulation of 
factors  (FAS,  E-cadherin  and  PTEN)  implicated  in  apoptosis,  invasion  and 
survival within the melanocytic tumors.   67 
 
2.3  Results 
 
Downregulation  of  RXRα  protein  in  epidermal  keratinocytes  during 
human melanoma progression  
   Our earlier studies demonstrated that loss of keratinocytic RXRα  in a non-
cell  autonomous  manner  regulated  melanocyte  homeostasis  during 
DMBA/TPA-induced  melanomagenesis  (Indra  et  al.,  2007).  It  has  been 
previously  shown  that  a  loss  of  nuclear  RXRα  protein  in  melanocytes 
correlates with melanoma progression in human patients (Chakravarti et al., 
2007).  We  therefore  investigated  expression  levels  of  RXRα  protein  in 
epidermal  keratinocytes  by  immunohistochemistry  (IHC)  of  normal  human 
skin, tumor adjacent normal (TAN) epithelium, benign nevi, in situ melanoma 
and  malignant  melanoma  samples  from  tissue  microarray  and  de-identified 
human  tissues.  Normal  and  TAN  epidermis  showed  strong  nuclear  RXRα 
expression in most, if not all, basal keratinocytes, as well as in the suprabasal 
layers (Figures 2.1A-D). The epidermis adjacent to benign nevi displayed a 
hyperplastic appearance that was also present in the in situ and malignant 
melanoma  samples.  Most  keratinocytes,  as  well  as  nests  of  nevus  cells, 
exhibited strong nuclear RXRα expression in the benign nevi (Figures 2.1E 
and 1F). A general trend of reduced expression (~50%) of RXRα protein was 
seen  in  suprabasal  keratinocytes  for  in  situ  melanomas  (Figures  2.1G  and   68 
 
2.1H,  Table  S1),  and  a  marked  absence  of  RXRα  protein  was  seen  in  all 
layers of epidermis from malignant melanoma samples (Figures 2.1I and 2.1J, 
Table S1). A Fisher's Exact test showed a significantly low probability (p < 
0.001) that loss of keratinocytic RXRα expression would be seen only in these 
two tissues, suggesting an association with metastatic progression in humans.   
 
Loss of keratinocytic RXRα in cooperation with activated CDK4 leads to 
larger melanocytic tumors in mice 
   Involvement  of  the  p16/CDK4  pathway  has  been  implicated  during 
melanomagenesis in humans (Curtin et al., 2005; Kamb et al., 1994; Wolfel et 
al., 1995; Zuo et al., 1996). We hypothesized that the increased melanocyte 
proliferation reported in our previous study (Indra et al., 2007) could be due to 
deregulated cell cycle control. Additionally, the use of activated CDK4, paired 
alongside a secondary genetic alteration of melanocytic signaling pathways, 
has  been  shown  to  promote  formation  of  metastatic  melanomas  in  mouse 
models (Hacker et al., 2006; Tormo et al., 2006). We therefore investigated the 
cooperative  effects  of  activated  CDK4,  in  parallel  with  loss  of  keratinocytic 
RXRα, towards melanoma metastasis. To that end, we have bred the RXRα
ep-
/- and CDK4
R24C/R24C mice to generate RXRα
ep-/-/CDK4
R24C/R24C bigenic mice 
and utilized the two step carcinogenesis (DMBA/TPA) protocol (DiGiovanni, 
1992). RXRα
L2/L2 (floxed RXRα mice containing LoxP sequences flanking exon   69 
 
4)  mice  were  used  as  wild-type  controls,  and  those  with  single  mutation 
(RXRα
ep-/- and CDK4
R24C/R24C) served as additional controls. Although all mice 
in each cohort developed melanocytic tumors (MT) within the timecourse of 
the study, a greater number of MTs grew to sizes larger than 2mm in diameter 
in  both  the  RXRα
ep-/-  and  RXRα
ep-/-/CDK4
R24C/R24C  mice  compared  to  the 
RXRα
L2/L2  or  CDK4
R24C/R24C  mice.  Strikingly,  the  bigenic  mice  developed  a 
significantly higher number of MTs larger than 4mm in size compared to the 
RXRα
ep-/-  mice  (Figure  2.2A,  Figure  S2.1).  The  appearance  of  melanocytic 
tumors arose within a similar timeframe of 7-8 weeks in all treatment groups, 
however  decreased  tumor  latency  was  observed  in  mice  lacking  RXRα  in 
epidermal  keratinocytes  (Figures  S2.1B  and  S2.1C).  All  subsequent 
comparative  studies  were  performed  on  RXRα
ep-/-/CDK4
R24C/R24C  and 
CDK4
R24C/R24C  mice  to  determine  the  contribution  of  keratinocytic  RXRα 
signaling on melanomagenesis. 
   To  further  characterize  the  MTs  formed  in  the  dorsal  skin  of  the 
CDK4
R24C/R24C and RXRα
ep-/-/CDK4
R24C/R24C mice, we performed hematoxylin 
and eosin (H&E) staining of 5µm thick paraffin sections of melanocytic tumors 
from  both  genotypes  (Figure  2.2B).  A  significant  increase  in  epidermal 
thickness  was  observed  in  the  skin  from  RXRα
ep-/-/CDK4
R24C/R24C  skin 
compared to CDK4
R24C/R24C alone (Figure 2.2C). This phenotype is a hallmark 
of  mice  bearing  an  epidermal  ablation  of  RXRα,  as  the  basal  layer   70 
 
keratinocytes maintain a hyperproliferative state (Li et al., 2001). Importantly, 
both the radial growth phase (RGP) and vertical growth phase (VGP) of the 
MTs in the dermis were significantly increased in the bigenic mice compared 
to the control mice (Figure 2.2D). Similar results were seen when comparing 
the  bigenic  mice  to  both  RXRα
L2/L2  and  RXRα
ep-/-  mice  (data  not  shown). 
Altogether the above results suggest a synergistic effect of RXRα ablation and 
activated CDK4 in the development of cutaneous melanoma. 
 
Immunohistochemical  analyses  of  melanocytic  tumors  from  RXRα
ep-/-
/CDK4
R24C/R24C bigenic mice  
   We  performed  IHC  using  specific  antibodies  for  markers  of  proliferation, 
malignant  conversion,  and  vascularization,  to  further  characterize  the  MTs 
from  the  bigenic  mice.  Immunohistochemical  staining  was  performed  on 
paraffin  sections  of  tumors  taken  from  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C  mice  after  DMBA/TPA  treatment.  To  investigate  the 
mitogenicity of the MTs, we co-labeled with antibodies directed against the 
proliferation  marker  PCNA  and  the  melanocyte-specific  enzyme  tyrosinase 
related protein 1 (TRP1) (Jimenez et al., 1988; Waseem and Lane, 1990). A 
significantly higher percentage (67% vs 21%) of TRP1+ cells were co-labeled 
with PCNA (TRP1+/PCNA+) in the RXRα
ep-/-/CDK4
R24C/R24C skin compared to 
the  CDK4
R24C/R24C  skin  [(p  <  0.01),  Figures  2.3A  and  2.3B].  In  order  to   71 
 
determine the malignant nature of the MTs from the bigenic mice, IHC was 
performed  using  an  antibody  cocktail  directed  against  melanoma  antigens 
MART-1  and  HMB45  (Yamazaki  et  al.,  2005).  That  combination  showed 
increased  staining  in  all  of  the  MTs  from  the  RXRα
ep-/-/CDK4
R24C/R24C 
compared  to  the  CDK4
R24C/R24C  mice,  suggesting  a  larger  population  of 
malignant  cells  in  these  tumors  (Figures  2.3C  and  2.3D).  Similarly,  an 
increased immunoreactivity for the endothelial cell-specific marker CD31 was 
also detected in the bigenic mice (17% of DAPI positive cells) compared to 
CDK4
R24C/R24C  mice  (5%  of  DAPI  stained  cells),  suggesting  enhanced 
vascularization in the MTs from those mice (Wang et al., 2008) (Figures 2.3E 
and 2.3F). Altogether, these results (histopathological and IHC) confirm that 
the MTs from the bigenic mice have greater malignant tendencies compared 
to those from RXRα
ep-/- or CDK4
R24C/R24C mice. 
 
Cutaneous melanoma formed in the RXRα
ep-/-/CDK4
R24C/R24C bigenic mice 
metastasized to distal lymph nodes 
   In  order  to  determine  if  combinatorial  alterations  of  multiple  molecular 
pathways could activate a malignant neoplastic process, we analyzed draining 
lymph nodes and internal organs from RXRα
ep-/-/CDK4
R24C/R24C mice for the 
presence of metastatic melanocytes and compared them with lymph nodes 
from CDK4
R24C/R24C and RXRα
ep-/- mice. Both the subiliac lymph nodes from   72 
 
each  of  the  six  surviving  bigenic  mice  were  enlarged  and  hyperpigmented 
compared to only a single lymph node belonging to one of the eight control 
CDK4
R24C/R24C mice (Figures 2.4A and 2.4B). Additional distal organs did not 
exhibit  sign  of  metastasis  in  the  bigenic  or  control  mice  (data  not  shown). 
Fontana Masson staining for detecting melanin granules on paraffin sections 
identified the presence of numerous pigmented cell types in the bigenic lymph 
nodes, compared to an occasional pigmented cell found in the control mice 
(Figures 2.4C and 2.4D and data not shown). IHC analyses of lymph nodes 
using  an  antibody  raised  against  the  melanocyte-specific  enzyme  TRP1 
confirmed the presence of melanocytes in the draining lymph nodes from all 
the bigenic mice compared to only two of the control mice (Figures 2.4E and 
4F). Similarly, IHC analyses using a melanoma cocktail for detecting malignant 
melanocytes confirmed the presence of multiple malignant melanocytes in the 
bigenic mice compared to very few cells in the control lymph nodes (Figures 
2.4G  and  2.4H),  thus  corroborating  the  results  obtained  from  the  Fontana 
Masson staining. These results demonstrate that the RXRα
ep-/-/CDK4
R24C/R24C 
line  represents  a  melanoma  mouse  model  with  a  tendency  for  metastatic 
progression. 
 
Upregulation of mitogenic factors and regulatory proteins in the skin of 
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   It has previously been shown that various mitogenic growth factors secreted 
by  keratinocytes  exert  both  autocrine  and  paracrine  effects  in  the 
microenvironment  of  the  skin  and  contribute  to  melanoma  formation.  We 
therefore investigated if expression of specific soluble factors are altered in the 
skin of our bigenic mice. We also examined activation of regulatory proteins 
that lie downstream of those signaling pathways in both CDK4
R24C/R24C and 
RXRα
ep-/-/CDK4
R24C/R24C skin (Recio and Merlino, 2002; Tada et al., 2002). 
   To  determine  if  expression  of  genes  encoding  soluble  growth  factors  are 
altered at the transcriptional level, we utilized quantitative RT-PCR (qRT-PCR) 
to examine the relative mRNA levels in skin of RXRα
ep-/-/CDK4
R24C/R24C mice 
compared  to  the  CDK4
R24C/R24C  mice.  Significant  increases  in  mRNA 
expression level were seen for the paracrine factor Edn1 (~3.5 fold) in the skin 
of bigenic mice (Figure 2.5A). Similarly, expression of other factors such as 
Hgf (~1.5 fold), Fgf2 (~1.5 fold), Pomc (the precursor peptide of α-MSH, ~2 
fold) and Kitlg (~2 fold) were also upregulated in RXRα
ep-/-/CDK4
R24C/R24C mice. 
We then evaluated the transcription factor MITF that regulates expression of 
several  genes  implicated  in  proliferation,  survival  and  apoptosis  of 
melanocytes (Levy et al., 2006), since amplification of MITF has been linked to 
malignant  conversion  of  MTs (Garraway  et  al.,  2005).  Interestingly,  relative 
mRNA levels of Mitf-M, a melanocyte specific isoform, were also found to be 
increased (~1.5 fold) in the skin of RXRα
ep-/-/CDK4
R24C/R24C mice compared to   74 
 
the control group (Figure 2.5A). Similarly, relative mRNA levels of Il1α and 
Cox2  expression  were  significantly  upregulated  (~2  fold  and  ~1.5  fold, 
respectively), and a ~1.4 fold increase was seen in HbEgf transcript levels in 
the skin of bigenic mice (Luger and Schwarz, 1990; Tripp et al., 2003) (Figure 
2.5B). Protein levels and phosphorylation status of key MAPK protein family 
members  were  measured  to  determine  if  altered  MAPK  signaling  is 
responsible, at least in part, for increased melanomagenesis in the bigenic 
mice. A modest increase in expression level of p38, ERK and JNK proteins, 
and an increased phosphorylation of p38 and JNK, was seen in the skin of 
RXRα
ep-/-/CDK4
R24C/R24C  compared  to  CDK4
R24C/R24C  mice  (Figure  2.5C,  and 
data not shown).  
 
Nuclear receptor RXRα is recruited to the promoter of genes encoding 
paracrine factors EDN1 and HGF in keratinocytes 
   It is possible that absence of RXRα in keratinocytes is increasing the basal 
rate of transcription for specific soluble communication factors in the skin of 
RXRα
ep-/-/CDK4
R24C/R24C mice through a derepression mechanism. In order to 
verify  if  keratinocytic  RXRα  plays  a  direct  or  indirect  role  in  regulating  the 
expression of soluble growth factors at the transcriptional level, we performed 
ex vivo chromatin immunoprecipitation (ChIP) experiments on extracts from   75 
 
primary mouse keratinocytes and determined if RXRα protein is recruited onto 
the promoter of target genes.  
   The  promoters  of  numerous  keratinocyte-derived  soluble  growth  factors 
were  selected  as  potential  candidates  of  RXRα-mediated  cell  signaling.  A 
region  of  ~10kb  upstream  of  the  transcriptional  start  site  was  screened  for 
possible  binding  motifs  of  RXRα/NR  heterodimers.  Sequences  on  the 
promoters of Edn1, endothelin 3 (Edn3), fibroblast growth factor 7 (Fgf7), Hgf, 
p53,  proopiomelanocortin  (Pomc),  nerve  growth  factor  (Ngf),  nitric  oxide 
synthase (Nos) and Kitlg were targeted for further investigation and primers 
were  designed  to  capture  these  regions  (Figure  2.6A,  data  not  shown). 
Amplification of isolated chromatin using specific primers was performed on 
wild-type  primary  keratinocytes,  as  well  as  on  those  collected  from  mutant 
RXRα
ep-/- mice. Increased promoter occupancy by RXRα protein was detected 
by ChIP assay 1.4kb and 9.1kb upstream of the transcriptional start site of the 
Edn1  and  Hgf  gene  promoters,  respectively  (Figure  2.6B).  These  results 
suggest that RXRα is recruited to the promoter of paracrine mitogenic factors 
Edn1 and Hgf in murine keratinocytes. 
 
Altered  gene  expression  in  the  melanocytic  tumors  of  RXRα
ep-/-
/CDK4
R24C/R24C mice   76 
 
   Laser-capture microdissection (LCM) was performed on frozen sections of 
melanocytic tumors from CDK4
R24C/R24C and RXRα
ep-/-/CDK4
R24C/R24C mice to 
investigate  the  influence  of  RXRα  epidermal  ablation  on  melanoma 
progression.  Seventy  percent  of  the  pigmented  melanocytic  tumors  were 
extracted from the surrounding tissue (Figures S2.2A and S2.2B). Total RNA 
was  isolated,  amplified  and  converted  to  cDNA  to  evaluate  the  differential 
expression of genes commonly implicated in neoplastic processes by using a 
qPCR-based  gene  array  (Cancer  PathwayFinder  Array,  SABiosciences). 
Approximately 30 genes were differentially regulated more than 2-fold in the 
array,  pertaining  to  several  distinct  biochemical  processes,  and  data  was 
analyzed using the ddCT method (Figure 2.7A and Table S2.2). The death 
receptor Fas, which is involved in the extracellular response to apoptosis, was 
downregulated more than 7-fold. Other genes involved in apoptosis inhibition 
and  downregulated  in  the  mutant  melanocytic  tumors  were  caspase  8  (~5 
fold), Apaf1 (~3 fold), Bcl2l1 (~4 fold), Tnfrsf10b (~2 fold), Tnfrsf1 (~2 fold), 
E2f1  (~3  fold),  Chek2  (~3  fold),  Cdkn1a  (~2  fold),  while  Birc5/survivin  was 
upregulated (~3 fold). Elements of the plasminogen activation pathway, Plaur 
and Serpinb2, were up- and down-regulated (~2 and ~3 fold, respectively) in 
the RXRα
ep-/-/CDK4
R24C/R24C melanomas compared to those in CDK4
R24C/R24C 
tumors. Additionally, members of signal transduction and adhesion pathways 
which were upregulated included Cdkn2a (~5 fold), Itga4 (~2 fold), and Ffg1   77 
 
(~2  fold),  while  Syk,  Nfkbia,  Cdh1/E-cadherin,  Pten  and  Ctnnb1  were 
downregulated (~3, ~4, ~3, ~2 and ~2 folds, respectively) (Figure 2.7A). We 
performed qRT-PCR validation on LCM samples from control and bigenic mice 
for some of the interesting candidates implicated in melanomagenesis such as 
Fas and Birc5/survivin (apoptosis), Plaur and Cdh1/E-cadherin (invasion), and 
the tumor suppressor Pten. The results obtained further confirmed our initial 
PCR array data (Figure 2.7B). Furthermore, western blot validation was used 
to  determine  if  similar  changes  were  present  at  the  protein  level.  A 
downregulation in FAS, CDH1/E-cadherin and PTEN protein levels, and a mild 
upregulation  for  PLAUR  expression,  were  observed  in  the  bigenic  MTs. 
BIRC5/survivin was not detectable by either western blot or IHC in either group 
(Figure 2.7C and data not shown). Altogether, these results demonstrate a 
differential  regulation  of  apoptotic  and  invasive  mechanisms  within  the 
transformed melanocytes from the bigenic MTs.    78 
 
2.4  Discussion 
 
Formation of metastatic melanoma in RXRα
ep-/-/CDK4
R24C/R24C mice  
   We have shown that deletion of RXRα in keratinocytes contributes to the 
development of cutaneous melanoma after carcinogen treatment (Indra et al., 
2007). Since melanocytes in the previous study were not genetically modified, 
it suggests an influence of paracrine signal(s) from RXRα-ablated epidermal 
keratinocytes  on  melanocyte  biology  during  melanomagenesis.  Our  present 
study  demonstrated  that  the  addition  of  activated  CDK4  contributes  to  the 
malignant  transformation  and  metastatic  potential  of  proximal  melanocytes. 
IHC  studies  on  human  tissues  confirmed  decreased  expression  of  nuclear 
receptor  RXRα in  melanocytes  during  melanoma  progression,  thereby 
corroborating the results reported earlier (Chakravarti et al., 2007). In addition, 
we  showed  downregulation  of  RXRα  expression  in  tumor  adjacent 
keratinocytes  from  human  in  situ  and  malignant  melanoma  samples.  Our 
results  suggest  a  protective  role  of  keratinocytic  RXRα  against  aggressive 
tumor formation, the lack of which resulted in a significantly increased RGP 
and VGP in the bigenic RXRα
ep-/-/CDK4
R24C/R24C tumors. In order to achieve 
vertical growth, the nevus must acquire characteristics of both tumorigenicity 
and mitogenicity, properties that enable cellular proliferation within a foreign 
matrix (Hearing and Leong, 2006). The increase in PCNA
+/TRP1
+ cells within   79 
 
the  RXRα
ep-/-/CDK4
R24C/R24C  melanocytic  tumors  verified  the  presence  of  a 
large  population  of  proliferating  melanocytes.  Increased  staining  against 
melanoma antibody cocktail HMB45 and MART-1 detected in the RXRα
ep-/-
/CDK4
R24C/R24C  tumors  correlated  well  with  the  higher  VGP  in  those  mice. 
Similarly, CD31 staining in the bigenic skin implied that the larger MTs formed 
in those mice would necessitate additional vascular formation for nutritional 
support. Altogether, these data confirm that melanocytic tumors formed in the 
absence of keratinocytic RXRα, and in the presence of activated CDK4, have 
increased metastatic capabilities compared to the control mice. It has been 
previously  shown  that  the  loss  of  the  transcriptional  regulator  TAF4  in 
epidermal keratinocytes can lead to melanocytic tumors with invasion of lymph 
nodes  after  carcinogen  treatment  (Fadloun  et  al.,  2007).  It  remains  to  be 
determined  whether  TAF4  and  RXRα  act  through  the  same  or  different 
paracrine/juxtacrine pathways to regulate melanocyte homeostasis. Activating 
mutations in N-RAS and its downstream effector B-RAF are frequent events in 
human nevi and melanomas (Papp et al., 1999; Demunter et al., 2001; Garnett 
and  Marais,  2004).  Importantly,  N-RAS  and  B-RAF  mutations  are  mutually 
exclusive, strongly suggesting that both oncogenic activities are in the same 
linear  pathway  deregulating  the  mitogen  activated  protein  kinase  (MAPK) 
pathway.  Mice  bearing  oncogenic  N-RAS
Q16K  or  a  B-RAF
V600E  have  been 
shown to develop melanomas mimicking the genetics and pathology of the   80 
 
human disease (Ackermann et al., 2005; Dhomen et al., 2009). It is possible 
that keratinocytic RXRα mediated NR pathway(s) also cooperate with the N-
RAS
Q16K or B-RAF
V600E driven MAPK pathway towards melanoma progression 
in humans. 
 
Loss  of  keratinocytic  RXRα  and  increased  melanomagenesis  are 
associated with altered expression of paracrine growth factors 
   Previous  in  vitro  studies  have  confirmed  the  role  of  numerous  mitogenic 
factors  produced  in  and  released  from  keratinocytes  that  are  involved  in 
regulating  the  proliferation  and  differentiation  of  mammalian  epidermal 
melanocytes  through  receptor-mediated  signaling  pathways.  Among  those 
factors  are  EDN1,  α-MSH  (the  mature  cleavage  product  of  POMC),  HGF, 
KITLG  and  FGF2  all  of  which  have  profound  mitogenic  and  melanogenic 
effects on cultured mouse and human melanocytes (Abdel-Malek et al., 1995; 
Imokawa et al., 1992; Hirobe, 1992; Swope et al., 1995; Hirobe, 2001; Hirobe, 
2003; Hirobe, 2004). Enhanced secretion of most of these paracrine factors 
upon  loss  of  keratinocytic  RXRα  could  potentially  mediate  increased 
mitogenesis and melanomagenesis in the bigenic mouse model. Interestingly, 
increased secretion of most of these paracrine factors have been seen in the 
skin of neonatal RXRα
ep-/- mice after UV exposure (Wang et al., 2011)    81 
 
   Downstream effectors that propagate signaling cascades initiated by these 
ligand-receptor  interactions  are  not  mutually  exclusive  of  each  other,  but 
instead interact through crosstalk at multiple levels, such as the activation of 
RAS-MAPK pathway (van Biesen et al., 1995). It is noteworthy that the stress 
activated kinases p38 and JNK, both of whose expression and subsequent 
phosphorylation were enhanced in the skin of RXRα
ep-/-/CDK4
R24C/R24C mice, 
have  been  shown  to  lie  downstream  of  HGF/MET  signaling  pathways  and 
activate proliferation of melanoma cells (Recio and Merlino, 2002). We showed 
an  enhanced  expression  of  the  melanocyte  master  regulator  MITF  in  the 
mutant skin, whose expression is shown to be regulated by both MAPK and 
p38  signaling  (Vance  and  Goding,  2004  and  references  therein).  Although 
independence from other cell types is a hallmark of metastatic potential, it is 
possible  that  upregulation  of  mitogenic  factors  from  keratinocytes  into  the 
extracellular locale provides a pro-carcinogenic environment for melanocytic 
transformation (Haass and Herlyn, 2005).  
   Our ex vivo ChIP data demonstrated that RXRα/NR dimer was recruited on 
the promoter of both Edn1 and Hgf genes in murine keratinocytes. It has been 
previously shown that absence of RXR/NR dimers from the regulatory regions 
of the soluble cytokine Tslp lead to a dramatic increase in transcript levels for 
Tslp  (Li  et  al.,  2006).  We  propose  a  similar  model  of  derepression  on  the 
promoters  of  specific  soluble  growth  factors  such  as  Edn1  and  Hgf  in  our   82 
 
RXRα
ep-/- mice that increases the basal transcriptional activity due to loss of 
RXRα/NR.  It  has  been  reported  that  UV  induction  of  POMC  is  directly 
controlled  by  p53  (Cui  et  al.,  2007).  Although  we  have  identified  potential 
RXR/NR  response  elements  on  the  promoters  of  both  p53  and  Pomc,  our 
ChIP  data  did  not  confirm  recruitment  of  RXRα  to  the  promoters  of  either 
gene, suggesting an alternative mechanism(s) of Pomc regulation by RXRα.  
 
Molecular alterations of apoptosis, invasion and mitogenic signaling in 
the malignant melanomas from RXRα
ep-/-/CDK4
R24C/R24C mice 
   We  used  LCM  technology  to  show  the  inherent  functional  differences 
between  the  melanocytic  tumors  from  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C mice. A significant downregulation of the death receptor Fas, 
which  has  been  linked  to  apoptotic  resistance  in  melanocytic  lesions  and 
melanoma  cell  lines  (Bullani  et  al.,  2002),  was  observed  in  the  MTs  from 
bigenic mice. The ability to disregard pro-apoptotic external stimuli in these 
transformed  melanocytes  would  confer  a  selective  advantage  for  both 
malignant  transformation  and  therapeutic  resistance  (Ivanov  et  al.,  2003; 
Niedojadlo  et  al.,  2006).  There  was  also  an  upregulation  of  the  caspase 
activation inhibitor Birc5/Survivin, which is shown to be highly expressed in 
malignant  melanoma  but  absent  in  normal  melanocytes  (Grossman  et  al., 
1999;  Ryu  et  al.,  2007),  suggesting  that  melanomas  from  RXRα
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/CDK4
R24C/R24C  mice  might  utilize  multiple  pathways  to  attenuate  apoptotic 
signals. 
   The  invasion-linked  gene  Plaur  was  expressed  at  a  higher  level  in  the 
microdissected RXRα
ep-/-/CDK4
R24C/R24C melanomas. Although the process is 
poorly understood, the plasminogen-activation system has been shown to play 
an important role in hypoxic-induced metastasis through the upregulation of 
the receptor PLAUR (Rofstad et al., 2002). Changes in expression levels for 
genes  related  to  adhesion  would  be  expected  between  tumor  types  with 
differing  metastatic  potential.  In  the  MTs  of  bigenic  mice,  we  showed  a 
downregulation of CDH1/E-cadherin expression, loss of which is a hallmark 
transition for metastatic progression (Hsu et al., 1996, Ryu et al., 2007). It is 
noteworthy that UV-induced production of EDN1 by keratinocytes is known to 
downregulate E-cadherin expression in both melanocytes and melanoma cells 
(Jamal  and  Schneider,  2002).  Finally,  a  downregulation  of  the  tumor 
suppressor PTEN was shown in melanomas from bigenic mice, as has been 
previously  reported  in  certain  cases  of  primary  melanomas.  Loss  of  PTEN 
favors melanoma formation by reducing apoptosis and promoting cell survival 
(Stahl et al., 2003; Tsao, et al., 2003).  
   Presently, there are concerted efforts toward producing mouse models that 
recapitulate  the  processes  of  human  cutaneous  melanoma  with  a  goal  of 
providing  effective  therapeutic  strategies  (Ibrahim  and  Haluska,  2009).   84 
 
Findings  have  led  to  recent  advances  in  targeted  therapy  against  factors 
implicated in melanoma progression (Solit et al, 2006; Bedikian et al, 2006), 
but  have  been  less  effective  in  preventing  metastases.  Further  studies  of 
mouse  models  investigating  the  individual  contribution  of  paracrine  factors 
during  melanomagenesis  are  necessary.  Additionally,  investigations  using 
sequentially timed ChIP and re-ChIP experiments are necessary to determine 
both  the  temporal  events  and  recruitment  cascades  of  regulatory  proteins 
specific to transcriptional regulation of growth factors such as Edn1 and Hgf. 
Screening for genetic polymorphisms for RXRα in keratinocytes, in addition to 
melanocytes, is warranted in human melanoma patients, as we demonstrate 
keratinocytic contributions to both melanomagenesis and metastatic spread.     85 
 
2.5  Materials and Methods 
 
Mice 
Generation of RXRα
ep-/- (Li et al., 2001) and CDK4
R24C/R24C (Rane et al., 1999) 
mice have previously been described. Cohorts of 8-10 sex and age-matched 
mice were shaved and treated with 50µg DMBA in 100µl of acetone. Five days 
after DMBA application, 5µg TPA in 200µl acetone was applied topically twice 
a week for up to 25 weeks. All mice were shaved weekly, and the number and 
size of melanocytic tumors were recorded. Mice were housed in our approved 
University Animal Facility with 12h light cycles, food and water were provided 
ad libitum, and institutional approval was granted for all animal experiments. 
 
Tissue Samples 
Keratinocytic  RXRα  expression  was  evaluated  using  normal  (n=30),  tumor 
adjacent  normal  (n=18),  benign  nevi  (n=27),  in  situ  melanoma  (n=3)  and 
malignant melanoma (n=128) skin sections from de-identified human samples 
(Oregon  Health  and  Sciences  University)  and  a  malignant  melanoma  array 
(Biomax, ME482). Skin samples and melanocytic tumors were collected from 
each  group  of  mice  25  weeks  after  DMBA/TPA  application,  fixed  in  4% 
paraformaldehyde, dehydrated and embedded in paraffin. 
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Histological analyses 
Skin and tumor sections (5µm thick) from mouse tissue samples were stained 
with hematoxylin and eosin (H&E) as previously described (Indra et al., 2007). 
Fontana-Masson  staining  was  performed  according  to  manufactures 
instructions (American MasterTech). All microscopic studies were performed 
using a Leica DME light microscope and analyzed using the Leica Application 
Suite software, version 3.3.1.  
 
Immunohistochemistry 
For DAB color reactions, human tissue sections were deparaffinized in xylene, 
dehydrated  through  graded  alcohols,  and  high  temperature  (20  minute,  hot 
water  bath)  antigen  retrieval  was  performed  on  5µm  sections  using  citrate 
buffer,  then  placed  in  0.3%  hydrogen  peroxide  to  quench  any  endogenous 
peroxidase  activity.  Sections  were  blocked  with  10%  normal  goat  serum  in 
PBS-Tween (0.05%) for 30 minutes to block nonspecific antibody binding and 
then  incubated  overnight  with  rabbit  anti-RXRα  polyclonal  antibody  (Santa 
Cruz,  1/300  dilution).  Secondary  antibody  staining  was  carried  out  with  a 
biotin-labeled  goat  anti-rabbit  antibody  (Jackson  ImmunoResearch,  1/1500 
dilution)  for  2hrs  at  room  temperature,  followed  by  incubation  with  a 
streptavidin-biotin  horseradish  peroxidase  complex  (Vector  Laboratories). 
Detection was done using DAB+ substrate (Vector Laboratories) for 5 minutes,   87 
 
then  counterstained  with  Harris  hematoxylin,  followed  by  dehydration  and 
mounting.  
For immunofluorescence staining studies, paraffin sections from mouse skin 
and  tumor  samples  were  rehydrated  and  processed  as  above.  Antigen 
retrieval was performed in hot water bath either using citrate buffer pH 6.0 
(TRP1,  PCNA  and  CD31  staining)  or  tris-EDTA  buffer  pH  9.0  (HMB45 
staining),  and  then  bleached  at  60°C  with  10%  H202  for  30-60  minutes. 
Primary antibody incubation was followed by three washes with PBS-Tween 
(0.05%)  before  addition  of  the  secondary  antibodies.  Nuclei  were 
counterstained  with  DAPI.  Finally,  sections  were  rinsed  with  PBS-Tween 
(0.05%), dehydrated through sequential alcohol washes and then cleared in 
xylene. Slides were mounted with DPX mounting media and allowed to dry 
overnight. The following antibodies were used for immunohistochemistry: anti-
Pep1 (kindly provided by V. Hearing, NIH), anti-PCNA (Abcam), anti-HMB45 + 
DT101  +  BC199  cocktail  (Abcam),  anti-CD31  (Abcam).  The  secondary 
antibodies used were goat anti-rabbit CY2 and goat anti-mouse CY3 (Jackson 
ImmunoResearch).  All  images  were  captured  using  either  a  Zeiss  AXIO 
Imager.Z1 with a digital AxioCam HRm, and processed using AxioVision 4.7 
and  Gimp  2.6.  Sections  stained  without  primary  antibody  was  used  as  a 
negative control, and all experiments were performed in triplicates. 
   88 
 
Real-time PCR 
Total RNA was extracted from either dorsal skin after DMBA/TPA treatment 
using  Trizol  (Invitrogen),  or  PicoPure  RNA  isolation  kit  (Arcturus)  for  LCM 
validation studies, and cDNA was created using SuperScript II RT (Invitrogen). 
Amplification  was  performed  on  an  ABI  Real  Time  PCR  machine  using  a 
QuantiTect SYBR Green PCR kit (Invitrogen), and all targets were normalized 
to Hprt, which was used as an internal control. All reactions were performed in 
triplicates using a minimum of three biological replicates from each group of 
mice.  Melting  curve  analyses  were  performed  to  ensure  the  specificity  of 
amplification. Statistical analysis was done with GraphPad Prism software. 
 
Western blot 
The skin biopsy or melanocytic tumor of each mouse was homogenized, and 
proteins were extracted
 with a lysis buffer (150mM NaCl, 50mM Tris pH 7.5, 
5mM EDTA, and
 1% Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate) 
containing protease inhibitors (2µg/ml Aprotinin, 2µg/ml Leupeptin, 100µg/ml 
Pefabloc and 1µg/ml Pepstatin). Equal amounts
 of protein extract (25µg) from 
each lysate were resolved using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis  and  transferred
  onto  a  nitrocellulose  membrane.  The  blots 
were blocked overnight with 5% nonfat dry milk and incubated with specific 
antibodies. The antibodies used were mouse anti-JNK (cat.
 no. sc-571, Santa   89 
 
Cruz  Biotechnology,  Santa  Cruz,  CA),  anti  p-JNK  (cat.
 no.  sc-6254,  Santa 
Cruz Biotechnology, Santa Cruz, CA), anti-p38 MAPkinase (cat. No. 9212, Cell 
Signaling Technology, Danvers, MA) and anti-phospho p38 MAPkinase (cat. 
No. 9211, Cell Signaling Technology, Danvers, MA), anti-FAS (cat. no. sc-716, 
Santa  Cruz  Biotechnology,  Santa  Cruz,  CA),  anti-uPAR  (cat.  no.  sc-10815, 
Santa Cruz Biotechnology, Santa Cruz, CA), anti-E-Cadherin (cat. no. 4065, 
Cell Signaling Technology, Danvers, MA) and anti-PTEN (cat. no. 9559, Cell 
Signaling Technology, Danvers, MA).   After incubation with the
 appropriate 
secondary  antibody,  signals  were  detected  using
 immunochemiluminescent 
reagents (GE Healthcare, Piscataway, NJ). Equal protein loading in each lane
 
was confirmed with anti-actin antibody (catalog no. A5060, Sigma-Aldrich, St. 
Louis, MO). 
 
Chromatin immunoprecipitation 
Briefly, primary keratinocytes from wild-type and RXRα
ep-/- mice were fixed in 
1% formaldehyde, washed and sonicated. A 10% input sample was removed 
and the remaining chromatin was immunoprecipitated with and without 3µg 
RXRα (Santa Cruz Biotechnology) antibody and incubated overnight. Protein 
G  Dynabeads  (Invitrogen)  were  added  and  the  chromatin  complexes  were 
washed  and  subjected  to  reversal  of  protein-DNA  crosslinks.  DNA  was 
recovered  using  phenol-chloroform  extraction  and  ethanol  precipitation,   90 
 
amplification  was  performed  on  an  ABI  Real  Time  PCR  machine  using  a 
QuantiTect SYBR Green PCR kit (Invitrogen). Experiments were performed a 
minimum of three times.  
 
LCM and PCR Array Cancer PathwayFinder 
Melanocytic  tumors  from  RXRα
L2/L2,  RXRα
ep-/-,  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C skin was collected after 25 weeks of DMBA/TPA treatment and 
embedded in OCT using isopentane-dry ice. Eight micron thick frozen sections 
were prepared and kept at -80°C to preserve RNA integrity. Sections were 
dehydrated  and  melanocytic  tumors  were  microdissected  using  a  PixCell  II 
(Arcturus). Total RNA was then extracted using a PicoPure RNA isolation kit 
(Arcturus) according to manufacturer instructions. Isolated RNA was amplified 
using the RT
2 Nano PreAMP cDNA Synthesis Kit (SABiosciences) according 
to  manufacturers  instructions.  The  cDNA  was  evaluated  using  a  Mouse 
Cancer PathwayFinder PCR Array System (SABiosciences) consisting of 84 
primer sets, as well as 5 housekeeping genes and multiple internal controls, 
according to manufactures instructions and evaluated using the ΔΔCt analysis 
method.  
 
Statistical analysis   91 
 
To  determine  the  probability  that  loss  of  epidermal  RXRα  should  not  differ 
between the five types of tissue, a 5x2 table was analyzed using a Fisherʼs 
Exact  test.  Quantification  of  TRP1+/PCNA+  double-positive  cells  within  the 
melanocytic tumors was determined by counting total number of TRP1 and 
PCNA positive cells, and expressed as a percentage of TRP1+ cells that also 
stained positive for PCNA. Multiple sections were analyzed and significance 
was  determined  using  a  Studentʼs  t-test.  Similarly,  the  number  of  CD31-
positive cells was counted within the tumors and expressed as a percentage of 
total  DAPI  stained  cells.  The  analyses  of  RXRα,  HMB45/MART-1, 
PCNA/TRP1  and  CD31  expression  were  independently  performed  by  two 
investigators. 
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Figure  2.1.    Reduced  expression  of  keratinocytic  RXRα  during  melanoma 
progression in human skin. Representative localization of RXRα protein within 
the  epidermis  of  normal  (A,B),  tumor  adjacent  normal  [TAN]  (C,D),  benign 
melanocytic nevi (E,F), in situ melanoma (G,H) and malignant melanoma [MM] 
sections  (I,  J).  Brown  staining  represents  RXRα expression  (except  for  the 
dermal pigmentation present in malignant melanoma sections), counterstained 
with  Harris  hematoxylin.  E,  epidermis;  D,  dermis.  Orange  dashed  line 
encompass  nests  of  nevus  cells,  yellow  dashed  lines  indicates  epidermal-
dermal junction. Scale bar = 33µm.   101 
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Figure  2.2.    Formation  of  larger  melanomas  in  RXRα
ep-/-/CDK4
R24C/R24C 
bigenic mice. (A) Size distribution of melanocytic tumors in RXRα
L2/L2, RXRα
ep-
/-,  CDK4
R24C/R24C  and  RXRα
ep-/-/CDK4
R24C/R24C  mice  after  DMBA/TPA 
treatment. The number of tumors, less than 2mm, 2-4mm and greater than 
4mm in diameter, were determined in the four groups of mice, as indicated. 
Values  are  expressed  as  mean  +/-  SEM.  (B)  Histological  analyses  of 
melanocytic  tumors  from  CDK4
R24C/R24C  and  RXRα
ep-/-/CDK4
R24C/R24C  mice. 
Hematoxylin  and  eosin  (H&E)-stained  5µm  thick  paraffin  skin  sections  of 
biopsies  taken  after  DMBA/TPA  treatment.  E,  epidermis;  D,  dermis;  HD, 
hypodermis. Scale bar = 62µm.  (C, D) Increased epidermal thickness, and 
higher  radial  growth  phase  (RGP)  and  vertical  growth  phase  (VGP)  of 
melanocytic  tumors  in  RXRα
ep-/-/CDK4
R24C/R24C  mice.  Statistical  significance 
was calculated using unpaired Studentʼs t-test with GraphPad Prism software. 
Statistical relevance indicated as follows; * = p < 0.05, ** = p < 0.01, *** = p < 
0.001.   103 
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Figure  2.3.    Immunohistochemical  (IHC)  characterization  of  melanocytic 
tumors  in  CDK4
R24C/R24C  and  RXRα
ep-/-/CDK4
R24C/R24C  bigenic  mice.  (A,  B) 
Enhanced  melanocyte  proliferation  in  melanocytic  tumors  from  RXRα
ep-/-
/CDK4
R24C/R24C mice as determined by co-labeling with anti-TRP1 [green] and 
anti-PCNA  [red]  antibodies.  (C,  D)  IHC  staining  for  malignant  melanocytes 
using a cocktail of antibodies directed against melanoma antigens HMB45 and 
MART-1  [red].  (E,  F)  Increased  vascularization  was  detected  by  anti-CD31 
antibody  [green]  in  melanocytic  tumors  from  bigenic  mice  compared  to 
CDK4
R24C/R24 alone. E, epidermis; D, dermis. Scale bar (in yellow) = 33µm. 
White dashed lines, artificially added, indicate epidermal-dermal junction. Blue 
color corresponds to DAPI staining of the nuclei.   105 
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Figure 2.4.  Lymph node metastasis in RXRα
ep-/-/CDK4
R24C/R24C mice. (A, B) 
Excised  draining  lymph  nodes  from  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C  mice  after  DMBA/TPA  treatment.  (C,  D)  Fontana-Masson 
staining  of  draining  lymph  nodes  from  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C mice after carcinogenic treatment. Melanin granules stain black 
and red corresponds to Nuclear Fast Stain. (E, F) IHC staining was performed 
using  antibodies  directed  against  TRP1  [green].  (G,  H)  IHC  staining  was 
performed using antibodies directed against HMB45 and MART-1 [red]. Scale 
bar (in yellow) = 33µm. Blue corresponds to DAPI staining of the nuclei.   107 
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Figure 2.5.  Increased expression of paracrine factors and regulatory proteins 
in  the  skin  of  RXRα
ep-/-/CDK4
R24C/R24C  mice.  (A)  Enhanced  expression  of 
mitogenic  paracrine  factors  and  regulatory  proteins  in  skin  of  RXRα
ep-/-
/CDK4
R24C/R24C  mice  compared  to  CDK4
R24C/R24C  mice  after  25  weeks  of 
DMBA/TPA treatment. Relative mRNA transcript levels of endothelin 1 (Edn1), 
hepatocyte growth factor (Hgf), Kit ligand (Kitlg), proopiomelanocortin (Pomc), 
fibroblast  growth  factor  2  (Fgf2)  and  microphtalmia-associated  transcription 
factor (Mitf) were measured. (B) Enhanced expression of autocrine factors in 
skin  of  RXRα
ep-/-/CDK4
R24C/R24C  mice  compared  to  CDK4
R24C/R24C  25  weeks 
after DMBA/TPA treatment. Relative mRNA transcript levels of heparin-binding 
EGF-like growth factor (HbEgf), interleukin 1-alpha (Il1a) and cyclooxygenase 
2 (Cox2) were measured. (C) Western blot analysis of different proteins in the 
mitogenic MAPK pathway on skin extracts from RXRα
ep-/-/CDK4
R24C/R24C [MT] 
and CDK4
R24C/R24C [CT] mice 25 weeks after DMBA/TPA treatment. Antibodies 
used  were  against  p38,  phospho-p38,  JNK,  phospho-JNK.  Data  (A  and  B) 
represents mean ± SEM. All reactions were performed in triplicates using skin 
samples  collected  from  a  minimum  of  three  different  mice  in  each  group. 
Statistical  analyses  were  done  using  GraphPad  Prism  software  and 
significance level (*) were set at p < 0.05. # = Not significant.   109 
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Figure  2.6.    Nuclear  receptor RXRα  associates  with  target  gene  promoter 
encoding soluble growth factors in primary keratinocytes. (A) Putative RXREs 
identified upstream of the transcriptional start site of genes for specific soluble 
growth  factors  such  as  Edn1,  Hgf,  p53,  Pomc  and  Kitlg.  Arrows  indicate 
position  of  primers  designed  to  capture  all  potential  binding  sequences, 
asterisks  (*)  indicate  location  of  results  shown  in  figure.  The  position  of 
transcriptional start site is indicated as +1, promoter diagrams not to scale. (B) 
Chromatin  immunoprecipitation  (ChIP)  assay  was  performed  on  primary 
keratinocytes using antibody against RXRα protein and results were analyzed 
by  qPCR  using  specific  primers  (indicated  in  A).  RXRα  association  on 
consensus sequences for RXRα/NR heterodimers located on the promoters of 
Edn1,  Hgf,  p53,  Pomc  and  Kitlg  genes  in  wild  type  keratinocytes  was 
compared to cells lacking RXRα protein or wild type cells immunoprecipitated 
with an irrelevant antibody. Endothelin 1, EDN1; proopiomelanocortin, POMC; 
hepatocyte  growth  factor,  HGF;  Kit  ligand,  KITLG.  Statistical  analyses  was 
done  by  Studentʼs  unpaired  T-test  using  GraphPad  Prism  software  and 
significance level (*) were set at p < 0.05.   111 
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Figure  2.7.    Altered  expressions  of  genes  in  laser  capture  microdissected 
(LCM) melanocytic tumors. (A) Relative fold change differences ≥ 2 of RXRα
ep-
/-/CDK4
R24C/R24C  mRNA  transcripts  taken  from  LCM  isolated  melanocytes 
compared to CDK4
R24C/R24C mice. Amplified cDNA was analyzed using a RT
2 
Nano  PreAMP  cDNA  Synthesis  Kit  and  evaluated  using  a  Mouse  Cancer 
PathwayFinder  PCR  Array  System.  Gene  expression  was  normalized  to  a 
panel  of  housekeeping  genes  (B2m,  Hprt1,  Rpl13a,  Gapdh,  Actb).  (B) 
Validation of PCR array results using relative mRNA transcript levels of Fas, 
Birc5, Plaur, Cdh1 and Pten from LCM captured melanocytes of CDK4
R24C/R24C 
and RXRα
ep-/-/CDK4
R24C/R24C mice treated with DMBA/TPA for 25 weeks. (C) 
Validation of PCR array results using western blot detection for protein levels 
in  both  RXRα
ep-/-/CDK4
R24C/R24C  [MT]  and  CDK4
R24C/R24C  [CT]  melanocytic 
tumors  using  antibodies  against  FAS,  PLAUR,  CDH1  and  PTEN.  All 
experiments were done using a minimum of three biological replicates from 
each group of mice. Data represents three individual experiments and in all 
cases are expressed as mean +/- SEM. Statistical significance was calculated 
using  unpaired  Studentʼs  t-test  with  GraphPad  Prism  software.  Statistical 
relevance indicated as follows; * = p < 0.05, ** = p < 0.01.    113 
 
 
 
 
 
Supplemental Figure 2.1.  Formation of aggressive melanoma in RXRα
ep-/-
/CDK4
R24C/R24C  bigenic  mice.  (A)  Representative  gross  morphology  of 
RXRα
L2/L2, RXRα
ep-/-, CDK4
R24C/R24C and RXRα
ep-/-/CDK4
R24C/R24C dorsal skin 
after  DMBA/TPA  treatment.  (B)  Rate  of  melanocytic  tumor  formation  from 
RXRα
L2/L2  and  RXRα
ep-/-  skin  after  25  weeks  of  DMBA/TPA  treatment.  (C) 
Rate  of  melanocytic  tumor  formation  from  CDK4
R24C/R24C  and  RXRα
ep-/-
/CDK4
R24C/R24C dorsal skin after DMBA/TPA treatment.   114 
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Supplemental Figure 2.2.  Laser captured microdissection on sections from 
melanocytic  tumors.  (A,  B)  Representative  pre-  and  post-laser  captured 
microdissection images taken from frozen sections of RXRα
ep-/-/CDK4
R24C/R24C 
melanocytic  tumors.  Red  dashed  line  indicates  melanocytic  cells  that  have 
been removed for RNA isolation. Scale bar = 62µm.   115 
 
 
 Table 2.1   Primer sequences used in RT-qPCR assays 
Gene  Sense  Antisense 
Edn1  5ʼ-ACTTCTGCCACCTGGACATC-3ʼ  5ʼ-GTCTTTCAAGGAACGCTTGG-3ʼ 
Hgf  5ʼ-AGGAACAGGGGCTTTACGTT-3ʼ  5ʼ-GCTGCCTCCTTTACCAATGA-3ʼ 
Kitlg  5ʼ-TCCGAAGAGGCCAGAAACTA-3ʼ  5ʼ-TCAGATGCCACCATAAAGTCC-3ʼ 
Pomc  5ʼ-GTACCCCAACGTTGCTGAGA-3ʼ  5ʼ-GACCTGCTCCAAGCCTAATG-3ʼ 
Fgf2  5ʼ-CGGTCACGGAAATACTCCAG-3ʼ  5ʼ-TATGGCCTTCTGTCCAGGTC-3ʼ 
Mitf  5ʼ-TGAAGCAAGAGCATTGGCTA-3ʼ  5ʼ-TAGCTCCTTAATGCGGTCGT-3ʼ 
HbEgf  5ʼ-GGACAGATCTGAACCTTTTCA-3ʼ  5ʼ-GCAGTAGTCCTTGTATTTCCT-3ʼ 
Il1α  5ʼ-TCACCTTCAAGGAGAGCCG-3ʼ  5ʼ-ATCTGGGTTGGATGGTCTCTT-3ʼ 
Cox2  5ʼ-TCAAAACCGTGGGGAATGTAT-3ʼ  5ʼ-AGGATGTAGTGCACTGTGTTT-3ʼ 
Fas  5ʼ- TATCAAGGAGGCCCATTTTGC-3ʼ  5ʼ- TGTTTCCACTTCTAAACCATGCT-3ʼ 
Birc5  5ʼ- GAGGCTGGCTTCATCCACTG-3ʼ  5ʼ- CTTTTTGCTTGTTGTTGGTCTCC-3ʼ 
Plaur  5ʼ- TGCCGGGGACCAATGAATC-3ʼ  5ʼ- GAGGGTCAGGAGCAGAGAG-3ʼ 
Cdh1  5ʼ- CAGGTCTCCTCATGGCTTTGC-3ʼ  5ʼ- CTTCCGAAAAGAAGGCTGTCC-3ʼ 
Pten  5ʼ- TGGATTCGACTTAGACTTGACCT-3ʼ  5ʼ- GCGGTGTCATAATGTCTCTCAG-3ʼ 
Hprt  5ʼ-TGACACTGGCAAAACAATGCA-3ʼ  5ʼ-GGTCCTTTTCACCAGCAAGCT-3ʼ   116 
 
 
Table 2.2   Primer sequences used in ChIP assays 
 
Gene  Sense  Antisense 
Edn1  5ʼ-GTTCTTAGTGACCTAAAGCTGCTG-3ʼ  5ʼ-GGAGTAGAGGCCAAAATAGACTCA-3ʼ 
Hgf  5ʼ-GGAGAGGGAGAAGGAGAGAGAG-3ʼ  5ʼ-ATAACTGGTCATGAGGGAATGG-3ʼ 
p53  5ʼ-GCACCGGTTCAAAGTCTGTATT-3ʼ  5ʼ-CTGGGAACGGTAATGCACTCTA-3ʼ 
Pomc  5ʼ-TTGGAGAGTCACAGAATATTCCAC-3ʼ  5ʼ-GGATGGATGGGTTTTCTTTATG-3ʼ 
Kitlg  5ʼ-AACTCCAGCCTCTGTGTGTGTA-3ʼ  5ʼ-TTTCCTGGGTTACAGAGAATGG-3ʼ   117 
 
SUPPLEMENTARY TABLE 2.1 
 
PROPORTION OF SAMPLES LACKING KERATINOCYTIC EXPRESSION OF 
RXRα 
 
TYPE OF SAMPLE 
TOTAL NUMBER OF  
SAMPLES 
ANALYZED 
LOSS OF EPIDERMAL  
EXPRESSION  OF 
RXRa 
Normal skin  30  0/30 
TAN
1 skin  18  0/18 
Benign nevi  27  0/13
2 
In situ melanoma  3  2/3 
Malignant 
melanoma 
128  4/5
3 
1Tumor adjacent normal
 
2For  benign  nevi  only  13  of  the  27  samples  analyze  had  epidermal  tissue 
present.
 
3For malignant melanoma only 5 of the 128 samples analyzed
 had epidermal 
tissue present.
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Supplemental  Table 2.2.    Relative fold changes of gene expression within 
melanocytic tumors from RXRα
ep-/-/CDK4
R24C/R24C bigenic mice. List of genes 
on Cancer PathwayFinder PCR array exhibiting a fold change greater than 2.  119 
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3.1  Abstract 
 
   Keratinocytes  contribute  to  melanocyte  activity  by  influencing  their 
microenvironment, in part, through secretion of paracrine factors. Here we discovered 
that p53 directly regulates Edn1 expression in epidermal keratinocytes and controls 
UV-induced melanocyte homeostasis. Selective ablation of EDN1 in murine epidermis 
(EDN1
ep-/-)  does  not  alter  melanocyte  homeostasis  in  newborn  skin  but  decreases 
dermal melanocytes in adult skin. Results showed that keratinocytic EDN1 in a non-
cell autonomous manner controls melanocyte proliferation, migration, DNA damage 
and  apoptosis after  UVB  irradiation.  Expression  of  other  keratinocyte  derived 
paracrine factors did not compensate for the loss of EDN1. Topical treatment with 
EDN1  receptor  (EDNRB)  antagonist  BQ788  abrogated  UV  induced  melanocyte 
activation and recapitulated the phenotype seen in EDN1
ep-/- mice. Altogether, present 
studies establish an essential role of EDN1 in epidermal keratinocytes to mediate UV 
induced melanocyte homeostasis in vivo.  
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3.2  Introduction 
 
   Endothelin 1 (EDN1) belongs to a group of related peptides (EDN1, EDN2 
and EDN3) encoded by separate genes. The mature 21-amino acid peptides 
are expressed in a variety of tissue types and activate two distinct G protein-
coupled receptors (EDNRA and EDNRB) with varying affinities (Yanagisawa et 
al.,  1988;  Arai  et  al.,  1990;  Sakurai  et  al.,  1990).  The  EDNRB  receptor  is 
required for melanocyte development from a neural crest lineage (Reid et al., 
1996;  Opdecamp  et  al.,  1998).  Mice  deficient  in  EDN1  have  respiratory 
complications  as  well  as  craniofacial  abnormalities  (Kurihara  et  al.,  1994), 
while  those  lacking  EDNRB  have  a  spotted  color  resulting  from  loss  of 
epidermal  melanocytes  (Hosoda  et  al.,  1994).  Although  EDN1  was  initially 
characterized  as  a  potent  vasoconstrictive  peptide,  it  also  functions  as  a 
keratinocyte-derived paracrine factor for melanocytes. Previous in vitro studies 
have  shown  that  ultraviolet  B  (UVB)  exposure  increases  secretion  of 
keratinocyte-derived  EDN1  which  regulates  proliferation,  melanogenesis, 
migration  and  dendricity  of  human  melanocytes  via  a  receptor-mediated 
pathway  (Imokawa  et  al.,  1992;  Imokawa  et  al.,  1995;  Hara  et  al.,  1995; 
Horikawa et al., 1995), and this stimulatory effect is dampened by the EDNRB 
antagonist BQ788 (Wu et al., 2004). There was also evidence that EDNRB 
serves  as  a  tumor  progression  marker  of  human  melanoma,  as  increased   122 
 
expression of EDNRB was found in human melanoma biopsies and usage of 
EDNRB antagonists inhibited melanoma growth (Demunter et al., 2001; Lahav 
et al., 1999). Additionally, EDN1 was shown to be upregulated in the epidermis 
of mice after UVB irradiation (Ahn et al., 1998), potentially contributing to the 
photoprotective effects of EDN1 on melanocytes (Kadekaro et al., 2005). The 
melanocytic response to UV exposure in mouse skin has been characterized, 
where follicular melanocytes migrate upward along the outer root sheath and 
populate  the  basal  layer  of  the  interfollicular  epidermis.  This  epidermal 
melanocyte population peaks around 72hrs post-UV and begins to decrease 
1-2  days  later  (Rosdahl  and  Szabo,  1978;  Walker  et  al.,  2009).  Melanin 
pigmentation  is  a  result  of  reciprocal  interaction  between  epidermal 
keratinocytes  and  follicular  melanocytes  through  production  of  various 
signaling molecules and activation of corresponding receptors on the target 
cells  (Slominski  et  al.,  2004;  Slominski  et  al.,  2005b).  However,  the  full 
spectrum of keratinocytic influence on melanocyte activity after UV exposure 
remains to be determined. 
   Our  previous  work  in  an  RXRα
ep-/-/CDK4
R24C/R24C  cutaneous  melanoma 
model  suggested  a  paracrine  contribution  by  several  keratinocyte-derived 
soluble  factors  including  EDN1  in  disease  progression (Hyter  et  al.,  2010). 
Here we discovered a direct in vivo transcriptional regulation of keratinocytic 
Edn1 by the tumor-suppressor p53 in epidermal keratinocytes in response to   123 
 
UV irradiation. We also demonstrate that in vivo disruption of keratinocyte-
derived EDN1 signaling in vivo alters melanocyte proliferation and decreases 
epidermal and dermal melanocyte populations in both normal and UV exposed 
mouse  skin.  EDN1  also  has  a  protective  role  against  UVR  induced  DNA 
damage and apoptosis. Similar effects on UV-induced melanocyte proliferation 
and DNA damage are observed in p53-null mice. Inhibition of EDN1 signaling 
by  topical  application  of  an  EDNRB  antagonist  BQ788  on  mouse  skin  has 
similar effects as epidermal EDN1 ablation. Furthermore, treatment of primary 
murine  melanocytes  with  BQ788  abrogates  signaling  downstream  of  this 
receptor.  These  findings  further  support  the  role  of  a  micro-environmental 
influence  driven  by  p53  in  keratinocytes  on  the  behavior  and  activation  of 
melanocytes. 
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3.3  Results  
 
Transcriptional  regulator  p53  directly  and  positively  regulates  Edn1 
expression in epidermal keratinocytes after UV irradiation  
We wanted to elucidate mechanism(s) of Edn1 regulation in keratinocytes in 
response  to  UV  radiation.  Induction  of  p53  after  UV  exposure  protects 
epidermal keratinocytes against DNA damage skin carcinogenesis (Jiang et 
al.,  1999),  and  directly  regulates  p21  expression  to  limit  cell  proliferation. 
Similar  regulation  of  Pomc  by  p53  in  epidermal  keratinocytes  has  been 
postulated to mediate UV-induced hyperpigmentation in murine skin (Cui et al., 
2007).  However,  this  linear  mode  of  action  does  not  fully  explain  the 
eumelanogenesis demonstrated by the melanogenic phenotype of POMC-null 
mice (Slominski et al., 2005a). To determine if p53 is an upstream regulator of 
Edn1 gene in epidermal murine keratinocytes, we performed in silico promoter 
analysis  using  the  fuzznuc  and  ConTra  programs.  Three  potential  p53 
consensus binding motifs were identified in proximal, mid and distal promoter 
region  of  Edn1  within  5kb  upstream  of  the  transcriptional  start  site  (Figure 
3.1A).  Additional  in  silico  studies  were  performed  on  the  human  EDN1 
promoter and potential p53 binding sequences were also discovered (Figure 
3.1A). To determine if p53 is recruited onto the promoter of murine Edn1, we 
performed  ex  vivo  chromatin  immunoprecipitation  (ChIP)  assay  on  extracts   125 
 
from primary keratinocytes exposed to UV irradiation using primers designed 
to capture the three regions, as well as the 3ʼ UTR region. p21, a p53 target in 
keratinocytes,  was  used  as  a  positive  control  (Liu  and  Pelling,  1995).  As 
reported earlier, amplification of isolated chromatin DNA revealed increased 
promoter  occupancy  by  p53  on  the  p21  promoter  following  UV  irradiation 
(UVR)  (Figure  S3.1C).  The  distal  promoter  region  (relative  to  the 
transcriptional  start  site)  of  Edn1  displayed  a  preferential  increase  in  p53 
binding  post-UVR  compared  to  other  regions  and  to  mock  irradiated  cells 
(Figure  3.1B).  These  results  suggest  a  possible  direct  regulation  of  Edn1 
expression  by  p53  in  epidermal  keratinocytes.  In  order  to  validate  these 
findings,  we  performed  RT-qPCR  analyses  for  Edn1  expression  in  the 
epidermis  of  both  wildtype  (WT)  and  p53-null  (p53
-/-)  adult  mice  after  UVR 
exposure. A significant decrease in the expression of Edn1 was observed in 
the epidermis of p53
-/- mice 8hrs post-UVR compared to wildtype skin (Figure 
3.1C).  Altogether,  these  results  establish  Edn1  as  a  direct  transcriptional 
target of p53 in murine keratinocytes.  
 
Keratinocyte specific ablation of EDN1 alters melanocyte homeostasis 
in the skin of adult mice 
The  in  vivo  role  of  keratinocyte-derived  EDN1  in  regulating  epidermal 
homeostasis  and  melanocyte  activity  is  unknown.  In  the  present  study,  we   126 
 
investigated the role of this signaling molecule on keratinocyte and melanocyte 
homeostasis in murine skin. To this end, floxed EDN1
L2/L2 mice (Huang et al., 
2002; Shohet et al., 2004)
 were bred with a K14-Cre deleter mouse strain, 
which drives expression of Cre-recombinase in the basal cells of developing 
epidermis,  thereby  generating  EDN1
ep-/-  mice  (selectively  lacking  EDN1  in 
murine epidermis). Deletion of Edn1 in presence of Cre was confirmed by PCR 
using specific primers on DNA isolated from neonatal EDN1
L2/L2 (control, CT) 
and EDN1
ep-/- mice skin (Figure 3.2A). RT-qPCR analyses on RNA isolated 
from  the  epidermis  of  CT  and  EDN1
ep-/-  mice  showed  a  significant 
downregulation of Edn1 transcripts in the mutant skin, confirming ablation of 
Edn1 in epidermal keratinocytes (Figure 3.2B). Basal levels of EDN1 mRNA 
seen in the EDN1
ep-/- skin are most likely due to less frequent Edn1 expressing 
cells within the dermal compartment. No compensatory up-regulation of Edn3 
(another  endothelin  family  member  expressed  in  skin)  transcripts  was 
observed by RT-qPCR in EDN1
ep-/- skin compared to CT skin (Figure 3.2B). 
Gross morphological examination did not reveal any difference between the 
skin of EDN1
L2/L2 and EDN1
ep-/- mice. 
   To  determine  whether  loss  of  keratinocytic  EDN1  altered  keratinocyte 
proliferation  and  differentiation  in  vivo,  we  performed  histological  and 
immunohistochemical  (IHC)  analysis  on  dorsal  skin  sections  from  CT  and 
mutant  neonatal  (P2)  and  adult  (P42)  mice.  Histological  analyses  on  H&E   127 
 
stained skin sections from CT and mutant mice did not reveal any differences 
in epidermal thickness between the two groups in the neonatal or adult skin 
(Figure  S3.2A,  B  and  S3.6A,  B,  C).  Furthermore,  expression  pattern  for 
markers of proliferation [Ki67, PCNA, keratin-14 (K14)] and differentiation [K10 
and loricrin] were similar between CT and EDN1
ep-/- P2 and P42 skin (Figure 
S3.2C, D and S3.6C and data not shown). These results indicate that loss of 
keratinocytic EDN1 is dispensable for normal epidermal homeostasis of the 
developing  and  adult  murine  epidermis.  Fontana-Masson  (FM)  and  TRP1 
(melanocyte specific marker) IHC staining on adult skin sections showed a 
significant decrease in the number of dermal melanocytes in the mutant skin 
compared to CT skin. However, no differences in dermal melanocyte number 
were observed between the neonatal CT and mutant skin (Figure 3.2C, D and 
E). Altogether, these findings suggest that EDN1 mediated paracrine signaling 
from  keratinocytes  is  necessary  for  maintenance  of  dermal  melanocyte 
populations in unirradiated adult murine skin.  
 
Role of keratinocytic EDN1 in regulating UV induced proliferation, DNA 
damage repair and apoptosis of melanocytes in vivo  
UV  irradiation  induces  secretion  of  EDN1  by  epidermal  keratinocytes 
(Imokawa et al., 1992). In order to investigate the effects of UV irradiation in 
absence  of  EDN1,  we  subjected  neonatal  EDN1
L2/L2  and  EDN1
ep-/-  mice  to 
UVR  exposure  and  analyzed  its  responses  on  skin  keratinocytes  and   128 
 
melanocytes. Briefly, P2 pups were exposed to a single dose of 600mJ/cm
2 
UVR and dorsal skin samples were collected after 24, 48, 72 and 96hrs post-
treatment. As reported earlier, Edn1 transcript level was significantly increased 
in the epidermis of CT
 skin at 24hrs post-UVR (Ahn et al., 1998) (Figure 3.3A). 
No Edn1 induction was observed in the mutant skin, further confirming Cre-
mediated  excision  of  Edn1  gene  in  their  epidermis  (Figure 3.3A).  Although 
Edn1 expression decreased in the CT skin after 24hrs post-UVR, its transcript 
level remained significantly higher at later timepoints compared to the EDN1
ep-
/- skin. RT-qPCR analyses did not reveal any compensatory upregulation of 
Edn3 transcript levels or alteration in the expression level of other keratinocyte 
derived  soluble  factors,  such  as  Fgf2,  Hgf,  Pomc  or  Kitlg,  in  the  EDN1
ep-/- 
neonatal  mice  skin  at  all  timepoints  post-UV  irradiation  (Figure  3.3A  and 
Figure S3.3A). These results suggest that any effects on melanocyte activity 
after UV exposure observed in the present study are solely due to the loss of 
EDN1. H&E staining on paraffin skin sections from CT and mutant mice did 
not reveal any differences in epidermal thickness between the CT and mutant 
skin post-UVR, implying that the loss of keratinocytic EDN1 did not influence 
UV-induced  epidermal  hyperplasia  (Figure  S3.6A  and  S3.6B).  To  further 
evaluate  any  altered  responses  to  UVR,  we  performed  FM  staining  for 
pigmented melanocytes on skin sections from CT and mutant mice at different 
timepoints after UV exposure. We did not observe an increase in epidermal   129 
 
melanocyte  population  until  72hrs  post-UVR  in  both  the  groups,  and  the 
number of epidermal and dermal melanocytes was significantly reduced in the 
EDN1
ep-/- skin compared to CT skin at 72 and 96hrs post-UVR (Figure 3.3B, C 
and D).  
   In  an  attempt  to  elucidate  the  mechanistic  basis  of  reduced  melanocyte 
population  from  the  hair  follicles  in  the  EDN1
ep-/-  skin,  IHC  analyses  was 
performed  on  CT  and  mutant  skin  to  investigate  the  proliferative  potential, 
DNA  damage  and  apoptotic  responses  of  melanocytes  post-UVR.  Co-
immunostaining of paraffin skin sections with proliferation markers PCNA or 
Ki67  with  TRP1  allowed  us  to  quantify  the  proliferative  responses  to  UV 
exposure in epidermis, dermis and melanocytes. A significant decrease in the 
number of proliferating melanocytes was seen in the mutant skin after 72hrs 
UVR using both the proliferation markers, which correlated with the decreased 
numbers of total melanocytes at that timepoint (Figure 3.4A and B and S3.5A 
and B, left panels). Similarly, IHC analyses for UVR induced DNA damage, 
using  co-labeled  anti-CPD  and  anti-TRP1  antibodies,  showed  a  significant 
decrease in clearance of thymine dimers in melanocytes from EDN1
ep-/- skin at 
the same timepoint (Figure 3.4A and B, middle panel). Analyses of melanocyte 
apoptosis  by  a  modified  TUNEL-IHC  assay  revealed  a  modest  increase  in 
apoptotic  melanocytes  at  24hrs  post-UV  irradiation  in  the  EDN1
ep-/-  skin 
compared to CT (Figure 3.4A and B, right panel). We did not observe any   130 
 
difference in the rate of proliferation, DNA damage or apoptosis in epidermal 
keratinocytes of the CT and mutant skin post-UVR (Figure S3.6C). Similarly, 
the dermal proliferation was comparable between CT and MT skin post-UVR 
at  all  timepoints.  However,  we  observed  a  decrease  in  DNA  damage  and 
apoptosis  in  the  dermis  after  72  and  24hrs  post-UVR,  respectively  (Figure 
S3.6D). Altogether, our in vivo results suggest that keratinocytic EDN1 alone is 
an important determinant of melanocyte homeostasis and plays a significant 
role in the proliferation and photoprotection of melanocytes after UV irradiation 
in neonatal mice.  
   In order to determine if the non-cell autonomous role of keratinocytic EDN1 
is  mediated  through  EDNRB  receptor  on  melanocytes,  selective  EDNRB 
antagonist BQ788 was applied to the dorsal skin of wildtype C57BL/6 neonatal 
mice concurrent with UVR exposure (Ishikawa et al., 1994; Lahav et al., 1999). 
A significant decrease in the number of epidermal melanocytes was observed 
by FM staining, and by IHC for TRP1+ cells, 72hrs post-UVR in the BQ788 
treated group compared to the vehicle treatment (Figure 3.3E). We did not 
notice  effects  on  the  dermal  melanocyte  population,  possibly  due  to  an 
inadequate penetration of BQ788 through the skin barrier (Figure S3.4C). No 
significant  difference  in  the  percentage  of  TRP1
+/PCNA
+  proliferating 
melanocytes was observed by IHC analyses between the two groups (BQ788 
vs vehicle) of mice (Figure S3.4C). Altogether, results demonstrated that in   131 
 
vivo blocking of EDNRB activity recapitulates the impaired paracrine effects on 
melanocytes observed in EDN1
ep-/- mice. Present results further support the in 
vivo  contribution  of  EDN1/EDNRB  signaling  pathway  to  UVR  induced 
melanocyte  activation,  migration  and  proliferation,  and  demonstrates  the 
feasibility of topical treatments for manipulating melanocyte activation in skin. 
 
Phenotypic similarities of the melanocytic response post-UV exposure 
between EDN1
ep-/- and p53
-/- mice 
The ability of p53 to bind and regulate melanogenic factors in mice has been 
previously  reported.  In  order  to  corroborate  our  findings  for  transcriptional 
regulation of murine Edn1 by p53, we utilized p53-null (p53
-/-) mice to evaluate 
the  melanocytic  response  after  UV-exposure.  FM  staining  and  IHC  utilizing 
antibodies  against  TRP1  showed  a  dramatic  decrease  in  the  number  of 
melanocytes  that  populate  the  murine  epidermis  72hrs  after  UV  exposure 
(Figure 3.5A). That was further verified by quantifying both the FM-positive 
and TRP1-positive cells to ensure that only those from the melanocytic lineage 
are counted (Figure 3.5B). Furthermore, IHC analyses for UV-induced DNA 
damage and melanocyte proliferation using anti-CPD and anti-PCNA or anti-
Ki67  antibodies  confirmed  a  significant  increase  in  DNA  damage-retaining 
melanocytes and a decrease in proliferating melanocytes in the p53-null skin 
(Figure 3.5C and S3.5A and B). Similar results were obtained after UVR in the   132 
 
EDN1
ep-/-  mice  skin  at  that  time  point.  Altogether,  our  results  support  an 
important  role  of  p53,  upregulated  following  UV  exposure,  to  bind  multiple 
factors and assist in the regulation of paracrine melanogenic networks. 
 
EDN1  mediates  activation  of  MAPK  and  PKC  signaling  through  its 
receptor EDNRB in murine melanocytes 
Previous studies in human melanocytes have highlighted the contributions of 
both  MAPK  and  PKC  activation  by  EDN1  signaling (Imokawa  et  al.,  1996; 
Sato-Jin et al., 2008; Imokawa et al., 2000). To verify expression of EDNRB 
receptor  in  keratinocytes  and  mature  murine  melanocytes,  we  performed 
immunoblots for EDNRB on lysates prepared from primary keratinocytes and 
melanocytes (Figure 3.6A). We hypothesized that lack of activation of MAPK 
and PKC pathways downstream of EDNRB in melanocytes contribute to their 
impaired  activation  and  proliferation  in  EDN1
ep-/-  mice.  To  test  that,  we 
investigated the effects of exogenous EDN1 on activation of those pathways in 
murine  melanocytes.  Briefly,  PKC  and  MAPK  activation  was  analyzed  in 
primary  murine  melanocytes  cultured  in  complete  or  minimal  medium 
supplemented  with  EDN1  and  in  presence  of  EDNRB  antagonist  BQ788. 
Western  blot  analyses  on  cell  extracts  from  melanocytes  conditioned  with 
complete  or  minimal  medium  supplemented  with  EDN1  indicated  strong 
phosphorylation of p42/p44 (pERK) proteins compared to those exposed to   133 
 
minimal  media  (Figure  3.6B).  Parallel  treatment  with  BQ788  completely 
abrogated  ERK1/2  phosphorylation,  indicating  EDNRB  receptor  mediated 
activation  of  MAPK  in  presence  of  EDN1  (Figure 3.6B).  Furthermore,  PKC 
activity  was  measured  to  confirm  activation  of  this  pathway  downstream  of 
EDNRB. Treatment of minimal medium with EDN1 induced PKC activation in a 
time-dependent  manner,  and  the  kinase  activity  was  completely  abolished 
upon treatment with BQ788, confirming the role of EDNRB receptor for this 
signaling  (Figure  3.6C).  Altogether,  above  results  confirm  EDNRB  receptor 
mediated  activation  of  downstream  MAPK  and  PKC  pathways  in  murine 
melanocytes  in  presence  of  exogenous  EDN1,  and  establishes  a  parallel 
between mouse and human melanocytes.  
   It is possible that the loss of keratinocytic EDN1 in our EDN1
ep-/- model leads 
to  decreased  follicular  melanocytes  migrating  along  the  upper  root  sheath, 
resulting in a lower population of epidermal melanocytes post-UV exposure. 
We therefore investigated the effects of exogenous EDN1 on the migration of 
wild type melanocytes using an in vitro real-time transwell migration assay. 
Results  indicated  that  EDN1  is  sufficient  to  increase  the  rate  of  transwell 
migration  of  cultured  melanocytes  compared  to  minimal  media  alone, 
supporting the role of keratinocytic EDN1 as a melanocyte chemoattractant 
(Figure 3.6D).    134 
 
   In order to determine the in vivo physiological effects of EDN1 signaling on 
melanocytes we further performed IHC for pERK on EDN1
L2/L2 and EDN1
ep-/- 
neonatal  mouse  skin  after  UV  exposure.  Strikingly,  there  was  a  strong 
induction  of  pERK  24hrs  after  UV  exposure  in  the  control  and  mutant 
epidermis (Figure 3.6E). That upregulation decreases at 48hrs and reverted to 
basal levels by 72hrs post-UVR (Figure 3.6E and F). Importantly, a similar 
induction of pERK was seen in follicular melanocytes as well, although that 
induction was modestly reduced in the skin of EDN1
ep-/- mice 24hrs post-UVR 
(Figure 3.6G). These results verify the in vivo activation of MAPK pathway in 
murine melanocytes post-UV exposure.   135 
 
3.4  Discussion 
 
   EDN1  contributes  to  human  melanogenesis  and  is  upregulated  in 
keratinocytes exposed to UVR. In the present study we discovered Edn1 is a 
transcriptional  target  of  p53  in  epidermal  keratinocytes  and  established  an 
essential  role  of  EDN1  in  regulating  melanocyte  homeostasis  and  UVR 
induced  photoprotection.  Our  previous  work  demonstrated  a  positive 
regulation of Edn1 by RXRα in murine keratinocytes (Hyter et al., 2010). That 
led us to investigate the mechanisms of regulation of this paracrine factor after 
exposure  to  the  solar  carcinogen  UVR.  Our  RT-qPCR  data  on  p53  null 
epidermis,  together  with  the  ChIP  assay  for  p53  recruitment  on  the  distal 
region  of  Edn1  gene  promoter  in  murine  keratinocytes  post  UVR,  have 
established p53 as a positive transcriptional regulator of Edn1 gene in UVR 
exposed mouse skin. Recently, multiple studies have investigated the role of 
p53  transcriptional  regulation  on  pigmentation  and  in  silico  analyses  have 
confirmed presence of p53 binding motifs on promoters of melanogenic factors 
KITLG and FGF2 (Wei et al., 2006). Concerning p53 regulated UVR induction 
of Pomc (precursor to α−MSH) (Cui et al., 2007), we were able to show a 
recruitment  of  p53  on  the  Pomc  promoter  in  murine  keratinocytes  (Figure 
S3.1A).  However,  under  our  experimental  conditions Pomc  transcript  levels 
were unaltered in the epidermis of p53
-/- mice before and after UV irradiation   136 
 
(Figure  S3.1B).  This  is  consistent  with  unaltered  melanin  pigmentation 
observed after Pomc deletion on the same genetic background (Slominski et 
al., 2005a), suggesting EDN1 signaling could provide alternate mechanisms of 
eumelanogenesis  within  the  skin.  Of  note,  melanocytes  are  known  to 
upregulate  expression  of  MC1R  in  response  to  EDN1  (Tada  et  al.,  1998). 
Elevated expression of p53 together with KITLG, EDN1 and POMC has been 
previously reported in the epidermis of hyperpigmented human skin, further 
suggesting a possible role of p53 in activating pigmentation networks (Murase 
et  al.,  2009).  Also,  ChIP  combined  with  a  yeast-based  assay  led  to  the 
identification of p53 binding sites on the promoter of EDN2, an EDN1 family 
member,  in  human  mammary  epithelial  cells  (Hearnes  et  al.,  2005).  The 
phenotypic  similarities  of  the  melanocytic  response  observed  between 
EDN1
ep-/-  and  p53
-/-  mice  post-UV  exposure  underscores  the  role  of 
keratinocytic  p53  to  regulate  expression  of  multiple  paracrine  factors  (e.g. 
EDN1) and mediate melanocyte homeostasis.  
   The loss of dermal melanocyte populations observed in unirradiated EDN1
ep-
/-  adult  mice  further  emphasizes  the  existence  of  paracrine  relationship 
between  keratinocytes  and  melanocytes  and  underscores  the  existence  of 
distinct signaling pathways in modulating epidermal vs. dermal melanocytes 
(Aoki et al., 2009). As this discrepancy in dermal melanocytes is only present 
in adult and not neonatal mice, it suggests a temporal aspect of EDN1-EDNRB   137 
 
signaling  during  post-developmental  homeostasis  and  emphasizes  EDN1 
function in maintenance of adult melanocyte homeostasis. Although epidermal 
melanocytes are absent in adult mouse skin compared to humans, resident 
dermal melanocytes are present (Fitzpatrick and Shiseidō, 1981). It is believed 
that  epidermal  melanocytes  and  dermal  melanocytes  represent  distinct 
populations of cells exhibiting different sensitivities to signaling factors (Aoki et 
al.,  2009;  Slominski  et  al.,  2005b).  Reliance  of  dermal  melanocytes  on 
EDN1/EDNRB signaling could partly account for the decrease in the number of 
viable dermal melanocytes in our EDN1
ep-/- mice model and establishes a non-
cell  autonomous  role  of  keratinocytic  EDN1  in  melanocyte  homeostasis. 
However, no alterations of epidermal proliferation and/or differentiation were 
seen  in  the  skin  of  EDN1
ep-/-  mice  due  to  the  loss  of  keratinocytic  EDN1, 
suggesting that EDN1 is dispensable for controlling epidermal homeostasis. 
That  was  in  agreement  with  an  earlier  report  showing  no  increase  in 
proliferation of cultured human keratinocytes in response to exogenous EDN1 
(Yohn et al., 1994). 
   Our  results  demonstrate  that  the  overall  decrease  in  the  melanocyte 
population observed 72 and 96hrs post UVR could be, at least in part, due to 
decreased melanocyte proliferation around that timepoint. The significant and 
paradoxical decrease of melanocyte proliferation 72hrs after UVR indicates a 
possible  temporal  role  of  EDN1-EDNRB  signaling  in  regulating  melanocyte   138 
 
homeostasis at the point when melanocytes are activated and migrating out of 
the hair follicles to repopulate the interfollicular epidermis (Walker et al., 2009). 
By  96hrs  post  UVR  the  percentage  of  proliferating  melanocytes  is  again 
similar  between  the  two  lines,  though  total  numbers  of  melanocytes  are 
decreased in EDN1
ep-/- skin, suggesting a response to alternative keratinocyte-
derived paracrine factors. In addition, the decrease in CPD clearance along 
with  increased  apoptosis  and  altered  melanocyte  migration  could  be  other 
potential  mechanisms  contributing  to  the  overall  decrease  in  melanocyte 
population  in  the  mutant  skin  post  UVR.  Previous  studies  utilizing  cultured 
human  melanocytes  have  demonstrated  the  contribution  of  EDN1 
supplementation  in  enhancing  melanocytic  proliferation  (Yada  et  al.,  1991). 
Our  present  in  vivo  observation  of  decreased  melanocyte  proliferation  in 
absence  of  keratinocytic  EDN1,  but  in  the  presence  of  other  diffusible 
paracrine factors (KITLG, HGF, FGF2 and α−MSH), further corroborates those 
in  vitro  studies.  The  synergistic  induction  of  multiple  UV-induced  paracrine 
factors such as EDN1, FGF2 and POMC-derived peptides makes it difficult to 
elucidate individual contributions in an in vivo model (Swope et al., 1995; Tada 
et al., 1998). Detecting EDNRB expression on primary murine melanocytes, 
along with a reduced number of proliferating epidermal melanocytes noted in 
our EDN1
ep-/- skin post-UVR, suggests a role for EDN1/EDNRB signaling in 
melanocyte activation. It has been previously shown that exogenous EDN1   139 
 
can protect cultured human melanocytes from UVR-induced apoptosis, while 
at the same time enhancing repair of CPD formations in those cells (Kadekaro 
et al., 2005). The reduced clearance of UVR induced thymine dimers and the 
modest increase in melanocyte apoptosis observed post-UVR in our EDN1
ep-/- 
mice further validates the previous in vitro findings. Our results suggest that 
cells of the melanocytic lineage have impaired CPD repair capacity in absence 
of  EDN1  signaling  compared  to  other  cell  types  of  the  skin,  thereby 
predisposing them towards neoplastic transformation. Similar phenotypes in 
p53
-/-  mice  further  support  the  importance  of  p53  signaling  to  the  UVR 
melanocytic  response.  Additional  studies  are  required  to  determine  which 
paracrine  factors,  besides  Edn1  and  Pomc,  are  upregulated  by  p53  in 
keratinocytes after UV exposure. 
   Our present results demonstrate that selective inhibition of EDN1 receptor 
(EDNRB) in cultured murine melanocytes abrogated downstream signaling by 
inhibiting PKC activation and MAPK pathway, corroborating previous results in 
human melanocytes (Imokawa et al., 1996; Imokawa et al., 2000; Sato-Jin et 
al.,  2008).  The  activation  of  MAPK  and  PKC  by  EDN1  in  cultured  human 
melanocytes is synergistically enhanced with the addition of KITLG (Imokawa 
et  al.,  2000),  supporting  the  role  of  multiple  keratinocyte-derived  signaling 
factors working in tandem to initiate melanocytic activity. Our in vivo IHC data 
for ERK activation suggest that loss of keratinocytic EDN1 did not significantly   140 
 
abolish  pERK  induction  in  melanocytes,  possibly  due  to  the  presence  of 
additional  keratinocytic-derived  paracrine  mitogenic  factors  in  the  cellular 
millieu.  Due  to  the  increasing  reliance  on  mouse  melanoma  models  for 
translational therapeutic approaches in humans, it is important to verify that 
comparable  transduction  mechanisms  exist  downstream  of  the  EDNRB 
receptor in murine melanocytes. Our data of reduced epidermal melanocyte 
population after topical treatment with EDNRB receptor antagonist supports 
our in vivo observation where expression of several UVR induced paracrine 
factors such as KITLG, α−MSH, HGF and FGF2 could not compensate for the 
loss of EDN1 in the murine epidermis. The modulation of MITF-M has been 
linked to EDN1 stimulation (Sato-Jin et al., 2008), thereby connecting growth 
factor receptor signaling to the master regulator of melanocytes. It has also 
been  previously  shown  that  contribution  of  EDN1  to  migration  of  human 
melanocytes is superior to FGF2, KITLG and a α−MSH analog (Horikawa et 
al., 1995; Scott et al., 1997). Our studies of melanocyte migration in presence 
or absence of EDN1 suggests a possible in vivo role of keratinocytic EDN1 in 
stimulating follicular melanocyte migration to the murine epidermis post-UVR.  
   Our  present  findings  shed  light  on  the  complex  interplay  between 
keratinocytes  and  melanocytes  in  skin  in  response  to  UV  irradiation  and 
provide  evidence  for  the  possibility  of  therapeutic  manipulation  of  those 
pathways.  We  discovered  that  p53  regulated  secretion  of  diffusible  factors   141 
 
such as EDN1 from epidermal keratinocytes can initiate signaling cascades 
within melanocytes and control melanocyte homeostasis in response to solar 
UV-irradiation. What is not currently understood is how these factors act in 
combination  to  establish  the  full  spectrum  of  receptor-mediated  cellular 
responses. Additional studies are necessary to further elucidate the temporal 
events  that  occur  post-UV  exposure  within  the  skin.  Understanding  how 
paracrine  factors  act  as  photoprotectors  against  DNA  damage  and  prevent 
malignant transformation of melanocytes in the cellular microenvironment is 
crucial for improved treatment of UV-induced skin cancers. 
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3.5  Methods 
 
Mice  
Generation  of  EDN1
L2/L2  mice  has  been  previously  described  (Huang  et  al, 
2002). To selectively ablate EDN1 in epidermal keratinocytes, mice carrying 
LoxP-site-containing (floxed) Edn1 alleles were bred with hemizygous K14-Cre 
transgenic  mice  (Li  et  al.,  2001)  backcrossed  to  a  C57BL/6  background  in 
order to generate EDN1
ep-/- mice in mendelian ratios. A semiquantitative PCR 
was performed in an Eppendorf thermal cycler using primers to amplify the 
Cre, L2 and L- Edn1 alleles. Mice were housed in our approved University 
Animal Facility with 12h light cycles, food and water were provided ad libitum, 
and institutional approval was granted for all animal experiments. 
 
UVR treatment  
P2 EDN1
L2/L2 and EDN1
ep-/- mice were exposed to a single dose of 600mJ/cm
2 
of UVB light from a bank of four Philips FS-40 UV sunlamps. The irradiance of 
the sunlamps was measured with an IL-1400A radiometer with an SEE240 
UVB detector (International Light). Mice were euthanized 24, 48, 72 and 96hrs 
after UVR and skin samples retrieved. 0hr samples were taken from P2 mice 
not exposed to UVR. Cohorts of 5 to 8 age-matched mice from multiple litters 
were  utilized  per  time  point.  C57BL/6  p53
-/-  adult  mice  were  exposed  to 
600mJ/cm
2 of UVB followed by biopsies taken at 8, 24 and 72hrs post-UVR,   143 
 
while C57BL/6 p53
-/- neonatal mice were treated with the same dosage at P3. 
   
BQ788 topical application  
BQ788 (A.G. Scientific) was dissolved in ethanol to a 200µM working solution 
and 20µl was applied to the dorsal skin of P1 C57BL/6 mice once a day for 
seven treatments. 600mJ/cm
2 UVB exposure was administered on day P3 and 
skin samples were collected 72 and 96hr post-UVR. Ethanol application alone 
was used for vehicle control samples. 
   
Histological analyses  
Skin biopsies were fixed and stained with hematoxylin and eosin (H&E) as 
previously  described  (Indra  et  al.,  2007).  Fontana-Masson  staining  was 
performed according to manufactures instructions (American MasterTech). All 
microscopic studies were performed using a Leica DME light microscope and 
analyzed using the Leica Application Suite software, version 3.3.1. 
   
Immunohistochemistry  
Immunofluorescence studies were performed as previously described (Hyter et 
al, 2010). The following antibodies were used for immunohistochemistry: anti-
PEP1 (kindly provided by V. Hearing, NIH, 1:1000), anti-PCNA (Abcam, ab29, 
1:6000), anti-CPD (Kamiya Biomedical Company, MC-062, 1:200), anti-pERK   144 
 
(Abcam, ab50011, 1:200), anti-Ki67 (Novocastra, NCL-Ki67-MM1, 1:200) and 
anti-EDN1  (Peninsula  Laboratories,  T-4050,  1:1000).  The  secondary 
antibodies used were goat anti-rabbit CY2 (1:400) and goat anti-mouse CY3 
(1:1000)  (Jackson  ImmunoResearch).  For  dual  TUNEL-IHC  staining,  the 
DeadEnd
TM TUNEL System (Promega) was combined with the above protocol. 
Sections stained without primary antibody was used as a negative control, and 
all experiments were performed in triplicates. All images were captured using 
a Zeiss AXIO Imager.Z1 with a digital AxioCam HRm and processed using 
AxioVision  4.7  and  Photoshop.  Data  were  analyzed  using  ImageJ  software 
(NIH), multiple IHC fields on each slide from all groups were randomly chosen 
and  10-15  fields  per  slide  were  counted.  The  slides  were  analyzed 
independently  in  a  double-blinded  manner  by  two  investigators  and 
significance was determined using a Studentʼs t-test. 
   
Reverse transcription–quantitative PCR (RT-qPCR) analyses  
Total RNA was extracted from whole dorsal skin or epidermal tail skin using 
Trizol (Invitrogen) and cDNA was created using SuperScript III RT (Invitrogen). 
Amplification  was  performed  on  an  ABI  Real  Time  PCR  machine  using  a 
QuantiTect SYBR Green PCR kit (Invitrogen), and all targets were normalized 
to the internal control Hprt. All reactions were performed in triplicates using a 
minimum of three biological replicates from each group of mice. Melting curve   145 
 
analyses  were  performed  to  ensure  specificity  of  amplification.  Statistical 
analysis was done with GraphPad Prism software. 
 
Immunoblotting analyses  
Primary C57BL/6 murine melanocytes were obtained from the Yale University 
Cell Culture Core. Cells were maintained in a complete melanocyte growth 
medium consisting of F-12 nutrient mixture (Ham), 8% FBS, bovine pituitary 
extract (25µg/mL), TPA (10ng/mL), 3-isobutyl-1-methylxanthine (22µg/mL) and 
1X  antibiotic/antimycotic.  Melanocytes  were  starved  into  a  quiescent  state 
using a minimal culture medium containing F-12 nutrient mixture (Ham), 8% 
FBS and 1X antibiotic/antimycotic for 72hrs prior to experiment. Cells were 
pre-incubated with the EDNRB antagonist BQ788 (A.G. Scientific) or vehicle in 
minimal culture medium for 60 minutes prior to treatment, followed by addition 
of EDN1 (Sigma). All treatments were prepared in minimal culture medium and 
cells  exposed  to  minimal  medium  alone  or  complete  melanocyte  growth 
medium  were  used  as  negative  and  positive  controls,  respectively.  At  the 
appropriate time points, protein lysates were obtained by collecting cells in a 
lysis buffer (20mM HEPES, 250mM NaCl, 2mM EDTA, 1% SDS, 10% glycerol, 
50mM  NaF,  .1mM  hemin  chloride,  5mM  NEM,  1mM  PMSF  and  10µg/mL 
leupeptin  and  aproptinin)  followed  by  sonication.  Protein  concentration  was 
performed using the BCA assay (Thermo Scientific). Equal amounts
 of protein   146 
 
extract (15µg) from each lysate were resolved using sodium dodecyl sulfate 
polyacrylamide  gel  electrophoresis  and  transferred
  onto  a  nitrocellulose 
membrane.  The  blots  were  blocked  overnight  with  5%  nonfat  dry  milk and 
incubated  with  specific  antibodies.  The  antibodies  used  were  rabbit  anti-
endothelin  receptor  B  (#AER-002,  Alomone  labs),  total  ERK  (#4695,  Cell 
Signaling) and phospho-ERK (#9101, Cell Signaling). After incubation with the
 
appropriate  secondary  antibody,  signals  were  detected  using
 
immunochemiluminescent reagents (GE Healthcare, Piscataway, NJ). Equal 
protein loading in each lane
 was confirmed with a b-actin antibody (#A300-
491, Bethyl). 
 
PKC kinase activity assay  
Murine melanocytes were grown and treated as described above. Cells were 
lysated  at  the  designated  timepoints  using  cold  lysis  buffer  (20mM  MOPS, 
50mM  β-glycerolphosphate,  50mM  sodium  fluoride,  1mM  sodium  vanadate, 
2mM  EGTA,  2mM  EDTA,  1%NP40,  1mM  DTT,  1mM  benzamidine,  1mM 
PMSF and 10µg/mL leupeptin and aproptinin). Cold lysates were collected and 
sonicated  to  ensure  disruption  and  cytosolic  fraction  was  collected  using 
centrifugation.  Protein  concentration  was  determined  as  described  above. 
Relative kinase activity was measured using the PKC Kinase Activity assay kit 
(Enzo) according to the manufacturers instructions.   147 
 
 
Real-time migration assay  
Murine  melanocytes  were  starved  into  a  quiescent  state  using  a  minimal 
culture medium for 48hrs prior to experiment as described above. Cells were 
seeded  into  a  CIM-plate  16  using  an  xCELLigence  system  (Roche)  at  a 
density  of  2x10
4  according  to  manufacturerʼs  instructions.  All  assays  were 
performed in triplicate and data analysis was performed using xCELLigence 
software. 
   
Chromatin immunoprecipitation  
Primary mouse keratinocytes from wild-type B6 pups were exposed without a 
lid to 10mJ/cm
2 UV irradiation. Fresh media was applied and the cells were 
allowed  to  incubate  for  2hrs.  Chromatin  precipitation  was  performed  as 
previously described (Hyter et al, 2010) using either 2µg of a p53 antibody 
(Santa Cruz Biotechnology) or non-specific IgG (Santa Cruz Biotechnology). 
Experiments were performed a minimum of three times. 
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Figure 3.1. Positive regulation of Edn1 expression after UV exposure by p53 
in murine keratinocytes. (A) Schematic of predicted p53 binding locations on 
murine and human Edn1/EDN1 promoters. Arrows indicate primers designed 
for chromatin immunoprecipitation (ChIP). (B) ChIP assay on primary murine 
keratinocytes using anti-p53 antibody following presence or absence of UV 
exposure. Results were analyzed by qPCR using primers specific to proximal, 
mid and distal regions (indicated in A). Primers directed against the 3ʼ UTR 
region of EDN1 and non-specific IgG antibody were used as negative controls. 
(C)  Relative  gene  expression  of  Edn1  in  epidermis  from  adult  wildtype 
C57BL/6  and  p53
-/-  mice  at  designated  time  points  post-UV  exposure.  All 
experiments were done using a minimum of three biological replicates from 
each  group  and  in  all  cases  are  expressed  as  mean  +/-  SEM.  Statistical 
analysis was performed using Graphpad Prism, * = p<0.05.   155 
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Figure 3.2. Characterization of EDN1
ep-/- mice showed reduced epidermal and 
dermal melanocytes in adult skin. (A) Schematic diagram of Cre-targeted loxP 
sites  flanking  exon  2  of  Edn1.  Genotyping  results  using  primers  directed 
against both Cre and Edn1 from epidermal genomic DNA. (B) qPCR analysis 
of mRNA expression levels for Edn1 and Edn3 in untreated P2 mouse whole 
skin are shown. (C,D) Fontana-Masson (black) and TRP1 (green) staining of 
untreated  P2  and  P42  mouse  dorsal  skin  sections,  arrows  indicate  dermal 
melanocytes; scale bar=20µm. IHC sections counterstained with DAPI (blue) 
and  white  dashed  lines  indicate  epidermal-dermal  junction.  (E)  Bar  graph 
comparing melanocytes per field between untreated P2 and P42 EDN1
L2/L2 
and  EDN1
ep-/-  skin.  All  experiments  were  done  using  a  minimum  of  three 
biological replicates from each group and in all cases are expressed as mean 
+/-  SEM.  Statistical  analysis  was  performed  by  Studentʼs  t-test  using 
Graphpad  Prism,  **  =  p<0.01.   157 
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Figure  3.3.  Decreased epidermal and dermal melanocytes in EDN1
ep-/- and 
BQ788-treated wildtype neonatal skin post-UVR. (A) Relative gene expression 
of Edn1 and Edn3 over time following UVR of EDN1
L2/L2 and EDN1
ep-/- P2 skin. 
(B) Fontana Masson (FM) stained images at 72 and 96hr post-UVR of P2 skin, 
arrows indicate melanocytes. Yellow dashed line represents epidermal-dermal 
junction,  scale  bar=20µm.  (C)  Epidermal  melanocyte  counts  per  field  in 
EDN1
L2/L2  and  EDN1
ep-/-  skin  over  time  post-UVR  of  P2  skin.  (D)  Dermal 
melanocyte counts per field in EDN1
L2/L2 and EDN1
ep-/- skin over time post-
UVR of P2 skin. (E) Epidermal melanocyte counts per field in wildtype B6 mice 
treated with topical BQ788 or vehicle at 72 and 96hrs post-UVR of P3 skin for 
both FM and IHC (TRP1+). All experiments were done using a minimum of 
three  biological  replicates  from  each  group  of  mice  and  in  all  cases  are 
expressed  as  mean  +/-  SEM.  Statistical  analysis  was  performed  using 
Graphpad Prism, * = p<0.05, ** = p<0.01, *** = p<0.001.   159 
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Figure  3.4.  Immunohistochemical  characterization  for  proliferation,  DNA 
damage  and  apoptosis  of  melanocytes  post-UVR.  (A)  IHC  analysis  of 
EDN1
L2/L2 and EDN1
ep-/- skin at 72 or 24hrs post-UVR of P2 mice stained with 
anti-PCNA (red), anti-CPD (red), anti-TRP1 (green and red) primary antibodies 
and TUNEL assay (green). Yellow scale bar=62µm, white scale bar=20µm. 
E=epidermis,  D=dermis,  HF=hair  follicle.  PCNA  and  CPD  sections 
counterstained with DAPI (blue) White dashed line indicates dermal-epidermal 
junction. (B) Percentage of PCNA, CPD or TUNEL-positive melanocytes out of 
total DAPI-stained cells between EDN1
L2/L2 and EDN1
ep-/- skin post-UVR of P2 
mice.  All  experiments  were  done  using  a  minimum  of  three  biological 
replicates from each group of mice and in all cases are expressed as mean +/- 
SEM. Statistical analysis was performed using Graphpad Prism, * = p<0.05. 
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Figure  3.5.  Decreased  epidermal  and  dermal  melanocytes  and  altered 
melanocyte proliferation and DNA damage in p53
-/- neonatal skin post-UVR. 
(A) Fontana Masson (FM) and IHC stained images of p53
+/+ and p53
-/- mouse 
skin at 72hr post-UV treatment of P3 mice, arrows indicate melanocytes. Anti-
PCNA (red), anti-CPD (red), anti-TRP1 (green) primary antibodies were used, 
PCNA and CPD sections counterstained with DAPI (blue). White dashed line 
represents  epidermal-dermal  junction,  E=epidermis,  D=dermis,  scale 
bar=62µm.  (B)  Epidermal  melanocyte  counts  per  field  using  both  FM+  and 
TRP1+  cells  72  hours  post-UVR  of  P3  skin  in  p53
+/+ and  p53
-/-  mice.  (C) 
Percentage of PCNA or CPD positive melanocytes out of total DAPI-stained 
cells between p53
+/+ and p53
-/- neonatal mice 72 hours post-UVR of P3 mice. 
All experiments were done using a minimum of three biological replicates from 
each  group  of  mice  and  in  all  cases  are  expressed  as  mean  +/-  SEM. 
Statistical analysis was performed using Graphpad Prism, ** = p<0.01, *** = 
p<0.001.  163 
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Figure  3.6.  Activation of MAPK and PKC signaling by EDN1 is specific to 
EDNRB receptor. (A) Immunoblot analysis of EDNRB expression in lysates 
from primary murine keratinocytes [KC] and melanocytes [MC], β-actin levels 
were used as controls. (B) Immunoblot analysis for ERK phosphorylation after 
addition of exogenous EDN1 with or without the EDNRB antagonist BQ788. 
Total ERK and β-actin levels were used as controls, as well as minimal and 
complete mediums. (C) Activation of PKC after addition of exogenous EDN1 
with or without the presence of EDNRB antagonist BQ788. All experiments 
were performed in triplicate and PKC activation results are expressed as mean 
+/-  SEM.  (D)  Real-time  transwell  migration  assay  comparing  slopes  for 
exponential migration phase of wildtype melanocytes. (E) IHC analysis of ERK 
activation in EDN1
L2/L2 and EDN1
ep-/- skin at 0, 24, 48 and 72hrs post-UVR 
treatment  of  P2  mice  with  anti-pERK  (red)  and  anti-TRP1  (green)  primary 
antibodies. All sections are counterstained with DAPI (blue), white dashed line 
represents  epidermal-dermal  junction.  E=epidermis,  D=dermis,  white  scale 
bar=62 µm, arrows and white boxes indicate pERK activated melanocytes. (F) 
Percentage of pERK+ cells out of total DAPI-stained epidermal cells between 
EDN1
L2/L2 and EDN1
ep-/- mice post-UVR treatment of P2 mice. (G) Percentage 
of  pERK+  melanocytes  out  of  total  TRP1+  stained  cells  in  EDN1
L2/L2  and 
EDN1
ep-/- after UVR treatment of P2 mice. All experiments were done using a 
minimum  of  three  biological  replicates  from  each  group  of  mice  and  in  all 
cases are expressed as mean +/- SEM. Statistical analysis was performed 
using Graphpad Prism, ** = p<0.01, *** = p<0.001.   165 
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Supplemental Figure 3.1. Regulation of Pomc expression after UV exposure 
by p53 in murine epidermis. (A) ChIP assay on primary murine keratinocytes 
using anti-p53 antibody with or without UV exposure. Results were analyzed 
by qPCR using primers specific to predicted p53 binding location on the Pomc 
promoter.  Non-specific  IgG  antibody  was  used  as  a  negative  control.  (B) 
Relative gene expression of Pomc in epidermis from adult wildtype B6 and 
p53
-/- mice at designated time points post-UV exposure. (C) ChIP assay for 
p53 occupancy on the p21 promoter of primary murine keratinocytes with or 
without UV exposure. Results were analyzed by qPCR using primers specific 
to p53 consensus sequence on p21 promoter. Non-specific IgG antibody was 
used as a negative control. All experiments were done using a minimum of 
three biological replicates from each group and in all cases are expressed as 
mean +/- SEM. Statistical analysis was performed using Graphpad Prism, ** = 
p<0.01.   167 
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Supplemental  Figure  3.2.  Keratinocytic  EDN1  ablation  does  not  influence 
epidermal homeostasis.  (A) Hematoxylin & eosin staining of adult EDN1
L2/L2 
and  EDN1
ep-/- skin.  Scale  bar=62µm,  E=epidermis,  D=dermis,  white  dashed 
line indicates epidermal-dermal junction. (B) Bar graph showing the epidermal 
thickness  of  EDN1
L2/L2  and  EDN1
ep-/-  adult  mice.  (C)  Representative  IHC 
analysis of adult skin stained with anti-Ki67 (red), anti-K14 (red), anti-K10 (red) 
and  anti-loricrin  (red)  primary  antibodies,  blue  represents  DAPI  nuclear 
staining,  arrows  indicated  Ki67-positive  keratinocytes.  Scale  bar  =  62µm, 
E=epidermis,  D=dermis,  white  dashed  line  indicates  epidermal-dermal 
junction.  (D)  Percentage  of  Ki67-positive  stained  keratinocytes  per 
microscopic field between EDN1
L2/L2 and EDN1
ep-/- adult mice.   169 
 
 
 
 
 
Supplemental Figure 3.3   170 
 
 
 
 
Supplemental Figure 3.3. Relative Edn1 mRNA expression was significantly 
lower in skin of EDN1
ep-/- neonatal mice post-UVR compared to EDN1
L2/L2. (A) 
qPCR analysis for relative mRNA expression at various time points post-UVB 
of  P2  mice.  Edn3=endothelin  3,  Fgf2=fibroblast  growth  factor  2, 
Hgf=hepatocyte  growth  factor,  Pomc=pro-opiomelanotropin,  Kitlg=Kit  ligand. 
All experiments were done using a minimum of three biological replicates from 
each  group  of  mice  and  in  all  cases  are  expressed  as  mean  +/-  SEM. 
Statistical analysis was performed using Graphpad Prism, ** = p<0.01, *** = 
p<0.001.   171 
 
 
 
 
Supplemental Figure 3.4   172 
 
Supplemental Figure 3.4. Topical application of BQ788 on wildtype neonatal 
skin  does  not  affect  dermal  melanocyte  populations  or  overall  melanocyte 
proliferation. (A) Representative FM staining of 72hr post-UVR skin sections 
from P3 B6 mice exposed to topical application of either vehicle or BQ788 
treatments.  Arrows  indicate  melanocytes,  yellow  dashed  line  represents 
epidermal-dermal junction, scale bar=62µm. (B) Representative IHC staining 
of  72hr  post-UVR  skin  sections  from  P3  C57BL/6  mice  exposed  to  topical 
application of either vehicle or BQ788 treatments. Antibodies directed against 
TRP1 (green) and PCNA (red) were used. Arrows indicate melanocytes and 
white dashed line represents epidermal-dermal junction, scale bar=62µm. (C) 
Graphical representation of dermal FM and epidermal IHC melanocyte counts. 
IHC counts were performed using both PCNA and TRP1 primary antibodies. 
Total  number  of  TRP1+  cells  were  counted  from  the  vehicle  and  BQ788 
treated groups from the 72 and 96hr post-UV timepoints. The percentage that 
were  co-labeled  PCNA+TRP1+  were  graphed,  all  experiments  were  done 
using a minimum of three biological replicates from each group of mice. Data 
represents  three  individual  experiments  and  in  all  cases  are  expressed  as 
mean +/- SEM. Statistical analysis was performed using Graphpad Prism.   173 
 
 
 
 
Supplemental Figure 3.5  174 
 
 
Supplemental  Figure  3.5.  Immunohistochemical  validation  of  melanocytic 
proliferation post-UVR. (A) IHC analysis of EDN1
L2/L2 and EDN1
ep-/- or p53
+/+ 
and p53
-/- skin at 72hrs post-UVR of P3 mice stained with anti-Ki67 (red) and 
anti-TRP1 (green) primary antibodies. Yellow scale bar=62µm, E=epidermis, 
D=dermis,  all  sections  counterstained  with  DAPI  (blue).  White  dashed  line 
indicates  epidermal-dermal  junction.  (B)  Percentage  of  Ki67-positive 
melanocytes out of total DAPI-stained cells between EDN1
L2/L2 and EDN1
ep-/- 
or  p53
+/+  and  p53
-/-  mice  post-UVR.  All  experiments  were  done  using  a 
minimum  of  three  biological  replicates  from  each  group  of  mice  and  in  all 
cases are expressed as mean +/- SEM. Statistical analysis was performed 
using  Graphpad  Prism,  *  =  p<0.05,  **  =  p<0.01.  175 
 
 
 
 
 
 
Supplemental Figure 3.6   176 
 
 
Supplemental  Figure  3.6.  Immunohistochemical  characterization  for 
proliferation, DNA damage and apoptosis of cutaneous cells post-UVR. (A) 
Representative H&E stained analysis of EDN1
L2/L2 and EDN1
ep-/- skin 72hrs 
post-UVR  of  P2  mice.  Scale  bar=62µm,  E=epidermis,  D=dermis,  HF=hair 
follicle. White dashed line indicates epidermal-dermal junction. (B) Epidermal 
thickness between EDN1
L2/L2 and EDN1
ep-/- skin post-UVR of P2 mice. (C-D) 
Percentage of PCNA, CPD or TUNEL-positive epidermal and dermal cells out 
of total DAPI-stained cells between EDN1
L2/L2 and EDN1
ep-/- skin post-UVR of 
P2  mice.  All  experiments  were  done  using  a  minimum  of  three  biological 
replicates from each group of mice and in all cases are expressed as mean +/- 
SEM. Statistical analysis was performed using Graphpad Prism, * = p<0.05, ** 
= p<0.01. 
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 Table 3.1   Primer sequences used in RT-qPCR assays 
Gene  Sense  Antisense 
Edn1  5ʼ-ACTTCTGCCACCTGGACATC-3ʼ  5ʼ-GTCTTTCAAGGAACGCTTGG-3ʼ 
Edn3  5ʼ-ACACGCTTGCGTTGTACTTG-3ʼ  5ʼ-TTTCTGCTCTCCCGGAATAA-3ʼ 
Hgf  5ʼ-AGGAACAGGGGCTTTACGTT-3ʼ  5ʼ-GCTGCCTCCTTTACCAATGA-3ʼ 
Kitlg  5ʼ-TCCGAAGAGGCCAGAAACTA-3ʼ  5ʼ-TCAGATGCCACCATAAAGTCC-3ʼ 
Pomc  5ʼ-GTACCCCAACGTTGCTGAGA-3ʼ  5ʼ-GACCTGCTCCAAGCCTAATG-3ʼ 
Fgf2  5ʼ-CGGTCACGGAAATACTCCAG-3ʼ  5ʼ-TATGGCCTTCTGTCCAGGTC-3ʼ 
Hprt  5ʼ-TGACACTGGCAAAACAATGCA-3ʼ  5ʼ-GGTCCTTTTCACCAGCAAGCT-3ʼ   178 
 
 
Table 3.2   Primer sequences used in ChIP assays 
 
 
Gene  Sense  Antisense 
Edn1 
Dist 
5ʼ- GCTGCTGTGTCTCCCCTACT -3ʼ  5ʼ- CCACAAAGGTCCCTTCTTCA -3ʼ 
Edn1 
Mid 
5ʼ- GCCAACGTGTTTTCTGTGTG -3ʼ  5ʼ- TGCGGTCTGTGCTTGATTAG -3ʼ 
Edn1 
Prox 
5ʼ- GGTGGTGGTGGAAAAGTAGG -3ʼ  5ʼ- GGGGCTGATCATTGTTCACT -3ʼ 
Edn1 
3ʼUTR 
5ʼ- CTTTTGTGGCTGGTTGACCT -3ʼ  5ʼ- CTAATGGCCTGCCAGAGAAG -3ʼ 
Pomc  5ʼ-CAGATGCGCCTTGCGCTCAG-3ʼ  5ʼ-ACCTTCCTGGCAGCGCTTC-3ʼ 
p21  5ʼ-CCTTTCTATCAGCCCCAGAGGATACC-3ʼ  5ʼ-GACCCCAAAATGACAAAGTGACAA-3ʼ   179 
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4.1  Conclusions 
    
   Malignant  melanoma  is  one  of  the  fastest  growing  cancers  in  the  United 
States  and  no  effective  therapeutic  options  are  available  once  the  primary 
tumor  has  disseminated  to  distal  organs.  Exposure  to  solar  UV  irradiation 
increases the risk of melanoma progression and many of these effects may be 
indirectly mediated through keratinocytic upregulation of various cytokines and 
growth  factors  that  function  as  paracrine  regulators  of  melanocyte 
homeostasis. In  vitro  culture  studies  of  melanocytes  in  keratinocyte-derived 
conditioned medium have elucidated key factors that contribute to the cellular 
communication  between  these  two  cell  types.  Histological  and  biochemical 
analyses of signal transduction pathways suggest influences of keratinocytes 
on  melanocyte  migration,  mitogenesis  and  melanogenesis,  particularly  after 
exposure to UV irradiation. The use of genetically engineered animal models 
allows  further  exploration  of  this  relationship  between  two  cell  types  by 
focusing  on  the  contribution  of  individual  soluble  factors  in  vivo  within  a 
functional  cellular  microenvironment.  Our  own  work  has  utilized  RXRα
ep-/-, 
RXRα
ep-/-/CDK4
R24C/R24C  and  EDN1
ep-/-  murine  models  to  investigate 
transcriptional regulation of epidermal keratinocyte-derived soluble factors in 
response  to  chemical  and/or  physical  carcinogens.  Our  studies  have  also 
established  keratinocytic  EDN1  as  a  critical  modulator  for  maintenance  of   181 
 
melanocyte homeostasis in adulthood and after UV irradiation. 
   Retinoid X Receptor α (RXRα), a member of the nuclear hormone receptor 
superfamily,  is  a  central  coordinator  in  transducing  cellular  signals  through 
heterodimerization  with  various  family  members.  RXRα  ablation  in  murine 
epidermal keratinocytes (RXRα
ep-/-) using Cre/loxP technology has provided 
evidence that RXRα is intimately involved in modulating expression of various 
keratinocyte-derived growth factors. An additional point mutation that activates 
cyclin dependent kinase 4 (CDK4) was used to create RXRα
ep-/-/CDK4
R24C/R24C 
bigenic mice that exhibited more aggressive melanocytic growths compared to 
RXRα
ep-/-  or  CDK4
R24C/R24C  alone  when  subjected  to DMBA/TPA  treatments 
(Chapter 2). The loss of keratinocytic RXRα induced secretion of paracrine 
growth factors into the tumor microenvironment. Evidence of recruitment of 
RXRα on the proximal promoter region of Edn1 and Hgf (relative to TSS) in 
murine  keratinocytes  suggests  transcriptional  regulation  of  these  genes.  In 
addition,  altered  expression  of  gene  networks  related  to  survival  and 
invasiveness within the melanocytic tumors was linked to loss of keratinocytic 
RXRα. Finally, evidence of decreased epidermal levels of RXRα protein during 
human melanoma progression correlated well with the results obtained in the 
mouse  studies.  Altogether,  results  demonstrate  the  cooperative  effects 
between  RXRα  and  CDK4  in  mediating  melanocyte  proliferation  and 
melanoma formation.    182 
 
   In order to determine the molecular basis of keratinocytic RXRα regulated 
expression  of  paracrine  factors  fully,  further  studies  investigating  the 
mechanism(s)  of  RXRα  binding  and  transactivation  properties  need  to  be 
performed.  Determining  the  expression  patterns  of  receptors  for  various 
paracrine  growth  factors  on  carcinogen-induced  melanomas  generated  in 
RXRα
ep-/- mice will corroborate previous studies in human samples (Loftus et 
al., 1999; Valesky et al., 2002; Sanchez-Mas et al., 2004; Curtin et al., 2006). 
Receptor  inhibition  using  small-molecule  or  antibody-based  antagonism  will 
reveal the importance of this keratinocyte-derived signaling in formation and 
malignant  progression  of  the  melanocytic  tumors  from  RXRα
ep-/-  mice. 
Although  we  have  gained  significant  insight  into  the  role  of  EDN1  in 
melanocyte  homeostasis,  additional  transgenic  mice  selectively  ablated  for 
other mitogenic factors such as KITLG, POMC and/or FGF2 would be useful to 
elucidate  their  contributions  in  regulating  melanogenesis  and  UV-induced 
melanocyte homeostasis. Analyses of conditioned media from UV-irradiated 
primary keratinocytes from RXRα
ep-/- or RXRα
ep-/-/CDK4
R24C/R24C bigenic mice 
will help to identify additional keratinocyte-derived soluble growth factors that 
are  released  in  the  microenvironment  and  can  modulate  melanocyte 
homeostasis. Isolation and characterization of such unknown proteins could 
establish novel molecular signaling between keratinocytes and melanocytes 
that could influence melanocyte homeostasis.   183 
 
   In  the  absence  of  agonistic  ligands,  RXRα/NR  heterodimers  act  as 
transcriptional  repressors  for  the  various  paracrine  growth  factors  as 
previously  described  for  thymic  stromal  lymphopoietin  (TSLP)  in  mouse 
keratinocytes in vivo (Li et al., 2006). Ligand binding to its cognate receptor 
can release the repression exerted by RXRα/NR corepressor complexes and 
enhance gene expression through modulation of cofactor complexes. In order 
to  reveal  the  identity  of  RXRα  heterodimeric  partner(s),  primary  murine 
keratinocytes  can  be  treated  with  various  NR  ligands.  Selective  retinoids, 
deltanoids,  thiazolidinediones,  oxysterols  and  other  NR  agonists  can  be 
utilized  to  determine  activation  of  specific  growth  factor  expression. 
Additionally,  computational  analyses  of  paracrine  gene  promoters  can  be 
useful  to  predict  RXR/NR  binding.  Those  in  silico  analyses  of  RXR/NR 
consensus  binding  motifs  can  be  partnered  with  chromatin 
immunoprecipitation  (ChIP)  sequencing  analyses  for  histone  activation  and 
repression  marks  to  provide  a  mechanistic  basis  for  RXR  regulation  of 
paracrine  factor  promoter(s).  Furthermore,  Co-IP  and/or  ChIP-reChIP 
experiments  investigating  the  sequential  association  of  RXRα  with 
components  of  the  transcriptional  activation  or  repression  complexes  will 
assist in determining the RXR/NR regulation of their target gene promoters. 
   Endothelins are signaling peptides composed of 21 amino acid residues that 
play a significant role in early melanocyte development, response to ultraviolet   184 
 
radiation  and  pathological  conditions  including  melanoma.  We  recently 
demonstrated  a  direct  recruitment  of  p53  on  the  distal  promoter  of  murine 
Edn1  and  a  positive  regulation  in  response  to  UV  treatment  of  primary 
keratinocytes. A mouse model harboring a selective ablation of keratinocytic 
EDN1 (EDN1
ep-/-) demonstrated disruption of melanocytic homeostasis in adult 
skin, while neonatal EDN1
ep-/- mice exhibit impaired melanocytic UV response. 
The  phenotypic  similarities  observed  between  EDN1
ep-/-  and  p53
-/-  mice, 
related to the altered melanocytic responses post-UV exposure, underscores 
the  role  of  keratinocytic  p53  to  regulate  expression  of  multiple  paracrine 
factors  (e.g.  EDN1)  and  mediate  melanocyte  homeostasis.  Finally,  we 
demonstrated that EDN1 produces a mitogenic response through the EDNRB 
receptor via pERK and activated PKC in cultured murine melanocytes and in 
murine skin in vivo (Imokawa et al., 1996; Sato-Jin et al., 2008; Hyter et al., in 
review). Our data also suggested that EDN1 stimulate melanocyte migration in 
vitro and additional studies are needed to reveal the underlying mechanisms. 
Details on how melanocytes are able to disconnect from a homeostatic niche 
and migrate towards an alternate tissue location during melanoma metastasis 
could  provide  druggable  targets  in  our  attempt  to  prevent  metastatic 
phenotypes of primary human melanomas. 
   It is important to establish ultraviolet (UV) irradiation as a causative agent for 
melanomagenesis. Melanoma resulting from neonatal UV exposure combined   185 
 
with  chronic  adult  treatment  can  provide  important  information  regarding 
driving  mutations  within  the  tumors.  Tyr-NRAS  mice  containing  activated 
NRAS  driven  by  the  tyrosinase  promoter  demonstrate  susceptibility  to 
melanoma formation (Ackermann et al., 2005). To establish the keratinocytic 
contribution towards solar UV-induced carcinogenesis, we bred our RXRα
ep-/- 
mice  to  this  line  and  have  created  a  novel  RXRα
ep-/-/TyrRAS+  mouse  to 
investigate the combinatorial effects of both these pathways in UVB-induced 
melanomagenesis.  Briefly,  two  days  old  (P2)  RXRα
L2/L2/TyrRAS+  (CT)  and 
RXRα
ep-/-/TyrRAS+ (MT) mice were subjected to 600mJ/cm
2 UVB irradiation 
and then chronically exposed to 300mJ/cm
2 UVB three times a week for 30 
weeks.  At  the  termination  of  the  treatment  period,  gross  morphological 
analyses  were  made,  skin  samples  were  collected  and  processed  for 
histological  and  immunohistochemical  analysis.  Whereas  both  lines 
experienced chronic UV-induced alopecia, all of the MT mice experienced a 
total  loss  of  hair  from  both  dorsal  and  ventral  side,  most  likely  due  to  the 
additive effects of keratinocytic loss of RXRα (Figure 4.1A). Histologically, CT 
and MT UV-irradiated adult mice skin displayed dermal pigmentation, due to 
NRAS activated melanocytes present in the hair follicles populating the dermal 
compartment (Figure 4.1B). However, after chronic UV treatment, the MT mice 
displayed denser pigmentation with melanocytes infiltrating into the basal layer 
keratinocytes and upper epidermis, reminiscent of the pagetoid spread seen in   186 
 
junctional melanoma (Chudnovsky et al., 2005; Chin et al., 2006). Melanoma 
cells  show  cytologic  atypia,  with  large  abundant  cytoplasm,  enlarged  and 
hyperchromatic  nuclei,  and  increased  overall  size  compared  with  normal 
melanocytes. Commonly, there was more junctional melanocytic hyperplasia 
(nests of tumor cells at the basement membrane zone). This is indicative of 
aggressive  melanocytes  transitioning  through  the  basement  membrane, 
potentially  drawn  by  increased  keratinocyte-derived  paracrine  signalling 
(Figure  4.1B).  The  MT  mice  also  developed  significant  numbers  of  dorsal 
dermal growths compared to the CT mice, demonstrating phenotypic changes 
attributed to the RXRα
ep-/- genotype (Figure 4.1C). 
Preliminary IHC analyses on skin sections co-labelled for melanocyte-specific 
marker TRP1 and the proliferation marker PCNA demonstrated a similar rate 
of proliferating melanocytes in the dermis of both CT and MT mice skin (Figure 
4.2A).  In  addition,  comparable  levels  of  expression  of  the  malignant 
melanocyte marker HMB45 were detected by IHC in both CT and MT mouse 
lines (Figure 4.2B). Finally, CD31 labelling for vessels displayed equivalent 
staining  in  both  RXRα
L2/L2/TyrRAS+  and  RXRα
ep-/-/  TyrRAS+  dorsal  skin, 
implying equal levels of vascularization within the pigmented dermis (Figure 
4.2C). Overall, chronic UV exposure in mice lacking keratinocytic RXRα paired 
alongside  activated  N-RAS  in  melanocytes  display  a  more  aggressive 
phenotype of epidermal invasion compared to those with activated RAS alone.   187 
 
Additional IHC studies for markers of immunoevasion and investigations into 
metastatic behaviour are needed to elucidate the cooperativity between the 
RAS  and  NR  signalling  pathways  during  melanoma  progression  and 
metastasis.  Similarly,  exposure  of  RXRα
ep-/-/CDK4
R24C/R24C  bigenic  mice  to 
solar UVB irradiation (physical carcinogen) instead of chemical carcinogen will 
present  a  more  natural  relationship  to  human  melanoma  development. 
Histopathological and immunohistochemical analyses of melanocytic tumors 
from those mice can then be compared to those from RXRα
ep-/-/TyrRAS+ mice 
to determine the cooperative effects between the multiple signalling pathways 
during melanomagenesis. Our present data and previous studies in mice and 
human  suggest  that  establishment  of  a  trigenic  RXRα
ep-/-
/TyrRAS+/CDK4
R24C/R24C  mouse  line  could  possibly  exhibit  enhanced 
melanomagenesis  and  increased  susceptibility  to  invasive  and  metastatic 
melanoma  formation  with  minimal  carcinogenic  stress.  (Ackermann  et  al., 
2005; Delmas et al., 2007; Contassot et al., 2012). 
 In  conclusion,  our  work  has  significantly  expanded  the  body  of  knowledge 
regarding  keratinocytic  influence  on  the  melanoma  microenvironment, 
especially the role of RXRα-mediated regulation of soluble mitogenic factors in 
chemical/physical  carcinogen  induced  melanomagenesis.  This  devastating 
disease  is  refractory  to  all  current  forms  of  treatment  and  our  studies 
investigating  mechanisms  underlying  micro-environmental  influences  on   188 
 
melanoma promotion and progression are important for the development of 
novel therapeutic targets to prevent and/or cure melanoma.   189 
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Figure 4.1   192 
 
Figure  4.1.  Phenotypic  and  histological  characterization  of 
RXRα
L2/L2/TyrRAS+ and RXRα
ep-/-/TyrRAS+ bigenic mice. (A) Representative 
gross  morphology  of  dorsal  skin  from  RXRα
L2/L2/TyrRAS+  and  RXRα
ep-/-
/TyrRAS+ after 30 weeks of chronic UV exposure. RXRα
ep-/-/TyrRAS+ mice 
develop dermal growths not seen in RXRα
L2/L2/TyrRAS+ mice. (B) Histological 
analyses of dermal pigmentation from chronic UV treated RXRα
L2/L2/TyrRAS+ 
and RXRα
ep-/-/TyrRAS+ skin. Hematoxylin and eosin (H&E)-stained 5µm thick 
paraffin skin sections of biopsies taken 30 weeks after birth, scale bar = 62µm. 
(C)  Representative  dermal  growth  and  graphical  analyses  of  endpoint 
formations present in Rxrα
ep-/-/TyrRas+ skin after UV treatment.  
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Figure 4.2. Immunohistochemical (IHC) characterization of cutaneous tissue 
in RXRα
L2/L2/TyrRAS+ and RXRα
ep-/-/TyrRAS+ bigenic mice. (A) IHC staining 
of bleached RXRα
L2/L2/TyrRAS+ and RXRα
ep-/-/TyrRAS+ skin sections after 30 
weeks of chronic UV treatment using both anti-TRP1 [green] and anti-PCNA 
[red] antibodies. (B) IHC staining for malignant melanocytes using a cocktail of 
antibodies directed against melanoma antigens HMB45 and MART-1 [red]. (C) 
Cutaneous vascularization detected by anti-CD31 antibody [red] within dermal 
tissure.  E,  epidermis;  D,  dermis.  Scale  bar  =  33µm.  White  dashed  line 
artificially added to indicate epidermal-dermal junction. Blue color corresponds 
to DAPI staining of the nuclei.  